SECTOR CAPITAL FUNDS PLC

(A company incorporated with limited liability as an open-ended umbrella investment company with variable capital under the laws of Ireland)

ANNUAL REPORT AND AUDITED FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021

Registration No. 489443

TABLE OF CONTENTS

GENERAL INFORMATION

Directors
Michael Boyce (*Irish*)^
Lars Tell *(Swedish)*
Conor Walsh *(Irish)*^

^Independent non-executive Director

Registered Office
32 Molesworth Street
Dublin 2
Ireland

Investment Manager
Harvest Funds AS *(resigned 5 February 2021)*
Kongens gate 12
N-0153 Oslo
Norway

Independent Auditors
Deloitte Ireland LLP
Chartered Accountants and Statutory Audit Firm
Deloitte & Touche House
Earlsfort Terrace
Dublin 2
Ireland

Investment Manager
Sector Funds Services AS *(appointed 5 February 2021)*
Kristian Augusts gate 15 C
N-0164 Oslo
Norway

Legal Advisers to the Company *(advisers as to Norwegian law)*
BAHR
Advokatfirmaet BAHR AS
Tjuvholmen allé 16
NO-0252 Oslo
Norway

Investment Manager
Sector Healthcare Value Fund
Sector Gamma AS
Kristian Augusts gate 15 c
N-0164 Oslo
Norway

Legal Advisers to Harvest Funds AS *(advisers as to Norwegian law)*
Thommessen
Haakon Vlls gate 10
Postboks 1484 Vika
NO-0116 Oslo
Norway

Administrator, Registrar and Transfer Agent
BNY Mellon Fund Services (Ireland) Designated Activity Company
Riverside Two
Sir John Rogerson's Quay
Grand Canal Dock
Dublin 2
Ireland

Legal Advisers to the Company *(advisers as to Irish law)*
Maples Group
75 St. Stephen's Green
Dublin 2
Ireland

Depositary
The Bank of New York Mellon SA/NV, Dublin Branch
Riverside Two
Sir John Rogerson's Quay
Grand Canal Dock
Dublin 2
Ireland

Sponsoring Brokers
Maples Group
75 St. Stephen's Green
Dublin 2
Ireland

Company Secretary
MFD Secretaries Limited
32 Molesworth Street
Dublin 2
Ireland

DIRECTORS' REPORT

The Directors present to the shareholders their annual report and the audited financial statements of Sector Capital Funds plc (the "Company") for the financial year 1 January 2021 to 31 December 2021.

Principal Activities and Review of Business

The Company was incorporated and registered in Ireland under the Companies Act 2014 as an open-ended umbrella investment company with variable capital and with segregated liability between sub-funds on 27 September 2010 with registered number 489443. The net assets of the Company were USD480,884,750 on 31 December 2021 (31 December 2020: USD492,002,331).

The Company was authorised by the Central Bank of Ireland pursuant to European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 (as amended) and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48 (1) (Undertakings for Collective Investment in Transferable Securities) Regulations, 2019 (as amended) (the "Regulations").

As at 31 December 2021, the Company has two funds in existence (31 December 2020: three), Sector Healthcare Value Fund and Harvest Equity Kernel (formerly Sector Global Equity Kernel). Harvest Equity Kernel ceased trading effective 15 January 2021. Effective 21 May 2021, Sector Sigma Nordic Fund's authorisation was revoked by the Central Bank of Ireland. An application will be made to the Central Bank of Ireland to have Harvest Equity Kernel's authorisation revoked.

Sector Healthcare Value Fund commenced trading on 17 November 2010. The base currency of Sector Healthcare Value Fund is United States Dollars ("USD"). As at 31 December 2021, fourteen classes are subscribed to in the Fund (31 December 2020: twelve), Class A EUR Shares, Class A NOK Shares, Class A USD Shares, Class B EUR Shares, Class B NOK Shares, Class B SEK Shares, Class B USD Shares, Class X USD Shares, Class X EUR Shares, Class Y EUR Shares, Class Y GBP Shares, Class Y USD Shares, Class E NOK and Class E USD.

Harvest Equity Kernel commenced trading on 19 March 2014. The base currency of Harvest Equity Kernel was USD. Effective 2 January 2020, the Fund changed its name from Sector Global Equity Kernel to Harvest Equity Kernel. As at 15 January 2021, the Fund ceased operations.

Results, Activities and Future Developments

The results of operations are set out on page 15. A detailed review of the business and future developments for the Funds is contained in the Investment Managers' Reports on page 9.

Statement of Directors' Responsibilities

The Directors are responsible for preparing the Directors' report and the financial statements in accordance with the Companies Act 2014 and the applicable Regulations.

Irish company law requires the Directors to prepare financial statements for each financial year. Under the law, the Directors have elected to prepare the financial statements in accordance with FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland ("relevant financial reporting framework"). Under company law, the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the Company as at the financial year end date and of the profit or loss of the Company for the financial year and otherwise comply with the Companies Act 2014.

In preparing those financial statements, the Directors are required to:

- select suitable accounting policies for the Company financial statements and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with the applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

DIRECTORS' REPORT (Continued)

Statement of Directors' Responsibilities (Continued)

The Directors are responsible for ensuring that the Company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the Company, enable at any time the assets, liabilities, financial position and profit or loss of the Company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' report comply with the Companies Act 2014 and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Audit Information Statement

So far as each of the Directors in office at the date of approval of the financial statements are aware:

- there is no relevant audit information of which the Company's auditors are unaware; and
- the Directors have taken all the steps that they ought to have taken as Directors in order to make themselves aware of any relevant audit information and to establish that the Company's auditor is aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of Section 330 of the Companies Act 2014.

Accounting Records

The Directors believe that they have complied with the requirements of Section 281 to 285 of the Companies Act 2014 with regard to the accounting records by employing the resources of an administrator, BNY Mellon Fund Services (Ireland) Designated Activity Company (the "Administrator"). During the financial year the accounting records of the Company were maintained at the offices of the Administrator: BNY Mellon Fund Services (Ireland) Designated Activity Company, Riverside Two, Sir John Rogerson's Quay, Grand Canal Dock, Dublin 2.

Fair Value Directive

It is the opinion of the Board of Directors that the information required by the European Communities (Fair Value Accounting) Regulations 2004, in relation to the use by the Company of financial instruments and the financial risk management objectives and policies of the Company and the exposures of the Company to market risk, currency risk, interest rate risk, liquidity risk and credit risk is contained in the Investment Managers' Report and note 7.

Significant events during the financial year

Upon recommendation from the Investment Manager, Harvest Funds AS, the Directors resolved to terminate Harvest Equity Kernel, with effect from 15 January 2021. The Directors will seek revocation of the approval of the Fund from the Central Bank of Ireland.

On 5 February 2021, Harvest Funds AS resigned as Investment Manager and with immediate effect Sector Funds Services AS was appointed as the Investment Manager.

A revised supplement for Sector Healthcare Value Fund was noted by the Central Bank of Ireland on 3 March 2021.

A revised supplement for Sector Healthcare Value Fund was noted by the Central Bank of Ireland on 18 May 2021.

Effective 21 May 2021, Sector Sigma Nordic Fund's authorisation was revoked by the Central Bank of Ireland.

A revised supplement for Sector Healthcare Value Fund was noted by the Central Bank of Ireland on 31 December 2021.

Market disturbances

The global public health crisis which arose from the outbreak of the novel coronavirus disease (known as COVID-19) has caused considerable volatility and disruption in financial markets since early March 2020. It is unknown what the impact will be on the global economy but the uncertainty and instability from COVID-19 for a prolonged period could have an adverse impact on the Company's or relevant Fund's business, opportunities, operations, financial condition and cash flows and there can be no assurance that the risks associated with COVID-19 will not alter significantly the attractiveness of an investment in the Company or a Fund as a result of the potential for capital losses and general uncertainty.

There were no other significant events during the year.

Significant events after the balance sheet date

We have assessed the possible impact on our business, to the extent possible, related to developments in Ukraine after 24 February 2022, as well as to sanctions imposed on Russia. The Company has no operations, investors, or suppliers in these countries. Trading counterparties are monitored from a risk perspective. The Company has no direct exposure to Ukraine or Russia.

There were no other significant events after the balance sheet date.

DIRECTORS' REPORT (Continued)

Business Continuity Planning

All relevant third party service providers, including the Investment Managers, have confirmed to the Board they have applied their contingency plans to ensure operational continuity in line with regulatory obligations of the Company. No operational disturbances have been identified as of now.

Directors

Michael Boyce
Lars Tell
Conor Walsh

Directors' and Secretary's Interests

The Directors and Secretary and their families had no interest in the shares of the Company at 31 December 2021, other than as disclosed below:

As at 31 December 2021, Lars Tell, Director of the Company held 326 Class A NOK shares in Sector Healthcare Value Fund (31 December 2020: 250 Class A NOK).

Dividends

Under the Articles of Association dividends may be paid out of the profits. During the financial years ended 31 December 2021 and 31 December 2020, no dividends were paid.

Corporate Governance Statement

The Company is subject to and complies with the Regulations.

The Board has adopted the voluntary Irish Funds ("IF") Corporate Governance Code for Irish domiciled Collective Investment Schemes and Management Companies, issued 14 December 2011 (the "Code") with effect from 11 December 2012. The Board has reviewed and assessed the measures included in the Code and considers its corporate governance practices and procedures since the adoption of the Code as consistent therewith.

The Company is subject to corporate governance practices imposed by:

1. The Irish Companies Acts 2014 and the Regulations which are available for inspection at the registered office of the Company and may also be obtained at www.irishstatutebook.ie.
2. The Articles of Association of the Company which are available for inspection at the registered office of the Company and at the Companies Registration Office in Ireland.
3. The Central Bank of Ireland in their Regulations which can be obtained from the Central Bank of Ireland's website at: www.centralbank.ie and are available for inspection at the registered office of the Company.

Financial Reporting Process - description of main features

The Board is ultimately responsible for overseeing the establishment and maintenance of adequate internal control and risk management systems of the Company in relation to the financial reporting process. As the Company has no employees and two of the Directors serve in a non-executive capacity, all functions including the preparation of the financial statements have been outsourced. The Company has appointed BNY Mellon Fund Services (Ireland) Designated Activity Company, as its administrator consistent with the regulatory framework applicable to investment fund companies such as the Company.

On appointing the Administrator, the Board noted that it was regulated by the Central Bank of Ireland and, in the Board's opinion, had significant experience as an administrator. The Board also noted the independence of the Administrator from the Company's Investment Managers. Subject to the supervision of the Board, the appointment of the Administrator is intended to manage rather than eliminate the risk of failure to achieve the Company's financial reporting objectives and can only provide reasonable and not absolute assurance against material misstatement or loss.

The annual and interim financial statements of the Company are required to be approved by the Board of the Company and filed with the Central Bank of Ireland. The statutory financial statements are required to be audited by independent auditors who report annually to the Board on their findings. The Board evaluates and discusses significant accounting and reporting issues as the need arises.

Risk Assessment

The Board is responsible for assessing the risk of irregularities whether caused by fraud or error in financial reporting and for ensuring that processes are in place for the timely identification of internal and external matters with a potential effect on financial reporting. The Board's appointment of an administrator independent of the investment manager to the Company and which is regulated by Central Bank of Ireland is intended to mitigate though not eliminate the risk of fraud or irregularities which may impact the financial statements of the Company.

DIRECTORS' REPORT (Continued)

Monitoring

The Board receives regular presentations and reviews reports from the Depositary, Investment Manager and Administrator. The Board also has an annual process to ensure that appropriate measures are taken to consider and address any control weaknesses identified and measures recommended by the independent auditors.

Capital structure

No person has a significant direct or indirect holding of securities in the Company. No person has any special rights of control over the Company's share capital. There are no restrictions on voting rights.

For the appointment and replacement of Directors, the Company is governed by its Articles of Association, Irish Statute comprising the Companies Acts 2014, the Regulations. The Articles of Association themselves may be amended by special resolution of the shareholders.

Composition and operation of the Board of Directors

There are three Directors currently, two of whom are non-executive and are independent of the Investment Manager. None of the Directors have entered into an employment or service contract with the Company. All related party transactions during the year are detailed in note 15 to the financial statements. The Articles of Association do not provide for retirement of Directors by rotation. However, the Directors may be removed by the shareholders by ordinary resolution in accordance with the procedures established under the Irish Companies Act 2014. The Board meets at least quarterly. There are no sub-committees of the Board.

The Board is responsible for managing the business affairs of the Company in accordance with the Articles of Association. Subject to its supervision and direction, the Board has delegated the day to day administration of the Company to the Administrator and the investment management and distribution functions to Sector Funds Services AS *(appointed 5 February 2021)*, Harvest Funds AS and Sector Gamma AS as the Investment Managers. The Company has appointed The Bank of New York Mellon SA/NV, Dublin Branch, as the Depositary to the Company with responsibility for the safekeeping of the assets of the Company.

Shareholder meetings

The convening and conduct of shareholders' meetings are governed by the Articles of Association of the Company and the Companies Act 2014. Although the Directors may convene an extraordinary general meeting of the Company at any time, the Directors are required to convene an annual general meeting of the Company within fifteen months of the date of the previous annual general meeting. Shareholders representing not less than 10% of the paid up share capital of the Company may also request the Directors to convene a shareholders' meeting. Not less than twenty one days' notice of every annual general meeting and any meeting convened for the passing of a special resolution must be given to shareholders and fourteen days' notice must be given in the case of any other general meeting unless the auditors of the Company and all the shareholders of the Company entitled to attend and vote agree to shorter notice.

On a show of hands every shareholder who is present in person or by proxy shall have one vote. On a poll every shareholder present in person or by representative or proxy shall have one vote for every share for which is registered in the name of the shareholder. Such voting rights may be amended in the same manner as any other provision of the Articles of Association.

Shareholders may resolve to sanction an ordinary resolution or special resolution at a shareholders' meeting. An ordinary resolution of the Company requires a simple majority of the votes cast by the shareholders voting in person or by proxy at the meeting at which the resolution is proposed. A special resolution of the Company requires a majority of not less than 75% of the shareholders present in person or by proxy and voting in a general meeting in order to pass a special resolution including a resolution to amend the Articles of Association.

Decision not to establish an Audit Committee

The Directors have decided not to establish an audit committee pursuant to section 167(2) (b) of the Companies Act 2014. This has been decided on the basis of the following:

a) the nature, scale and complexity of the Company's business range of services and activities undertaken in the course of that business;

b) the resources available to the Company and the resources and expertise of the various third parties engaged to support the Company and carry out certain functions on its behalf; and

c) the procedures in place for the review, approval and circulation of the audited financial accounts and statements which are appropriate for a self-managed investment company pursuant to the Regulations.

DIRECTORS' REPORT (Continued)

Independent Auditors

Deloitte Ireland LLP, Chartered Accountants and Statutory Audit Firm, have expressed their willingness to continue in office in accordance with Section 383(2) of the Companies Act 2014.

On behalf of the Board of Directors

DocuSigned by:
MJ Boyce
E1CF5842BDAF402...

DocuSigned by:
Conor Walsh
60A8A95D67E74E3...

Michael Boyce, Director

Conor Walsh, Director

Date: 22 March 2022

BNY MELLON

The Bank of New York Mellon SA/NV,
Dublin Branch
Riverside Two, Sir John Rogerson's Quay,
Grand Canal Dock, Dublin 2, D02 KV60,
Ireland.

T +353 21 438 0000
F +353 21 438 0295

REPORT FROM THE DEPOSITARY TO THE SHAREHOLDERS
DATED 22 MARCH 2022

For the period from 01 January 2021 to 31 December 2021 (the "**Period**")

The Bank of New York Mellon SA/NV, Dublin Branch (the "**Depositary**" "**us**", "**we**", or "**our**") has enquired into the conduct of Sector Capital Funds plc (the "**Company**") for the Period, in its capacity as Depositary to the Company.

This report including the opinion has been prepared for and solely for the shareholders in the Company, in accordance with our role as Depositary to the Company and for no other purpose. We do not, in giving this opinion, accept or assume responsibility for any other purpose or to any other person to whom this report is shown.

Responsibilities of the Depositary

Our duties and responsibilities are outlined in Regulation 34 of the of the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 (S.I. No 352 of 2011), as amended (the "Regulations").

Our report shall state whether, in our opinion, the Company has been managed in that period in accordance with the provisions of the Company's constitutional documentation and the Regulations. It is the overall responsibility of the Company to comply with these provisions. If the Company has not been so managed, we as Depositary must state in what respects it has not been so managed and the steps which we have taken in respect thereof.

Basis of Depositary Opinion

The Depositary conducts such reviews as it, in its reasonable opinion, considers necessary in order to comply with its duties and to ensure that, in all material respects, the Company has been managed (i) in accordance with the limitations imposed on its investment and borrowing powers by the provisions of its constitutional documentation and the appropriate regulations and (ii) otherwise in accordance with the Company's constitutional documentation and the appropriate regulations.

Opinion

In our opinion, the Company has been managed during the Period, in all material respects:

(i) in accordance with the limitations imposed on the investment and borrowing powers of the Company by the constitutional documentation and the Regulations; and

(ii) otherwise in accordance with the provisions of the constitutional documentation and the Regulations.

____
For and on Behalf of The Bank of New York Mellon SA/NV, Dublin Branch,
Riverside II,
Sir John Rogerson's Quay,
Grand Canal Dock,
Dublin 2

INVESTMENT MANAGERS' REPORTS

Sector Healthcare Value Fund

Healthcare stocks rose 19.8% in 2021 compared to a 21.8% gain for the broader equity markets, well supported by record inflows into passive index investment vehicles. US healthcare services stocks as well as the life sciences tools and services segment were best performing segments within the healthcare space. Biotech stocks and mid-cap stocks in general were the worst performing segments. Healthcare large-cap stocks outperformed mid- and small-caps to a degree not seen since the IT-bubble in 2000/2001. The Russel 2000 healthcare index fell 17.6% while the large-cap S&P healthcare index rose over 24% in 2021. Value stocks within healthcare underperformed for the year and has now underperformed consistently since 2016.

Sector Healthcare Value Fund ended the year up 11.2%. The Fund underperformed by a record 8.6% in 2021 in a difficult stock picking environment. Style factors were a headwind driven by healthcare value stocks underperforming and more significantly by mid-cap stocks dramatically underperforming their larger cap peers. The size exposure in the Fund, being overweight mid-caps and underweight ultra large caps, largely explains the underperformance in the Fund. Top performing positions for the full year, on a relative basis, were Novartis (underweight and subsequent overweight at good timing), Pfizer (Covid-19 vaccine and therapeutics winner), BioNtek (active trading), Bruker (LS tools bull market) and Vertex (underweight and subsequent overweight at good timing). Worst performing positions were holdings in Ionis (mid-cap biotech selloff and surprise convertible debt offering), Phillips (long standing product withdrawal/safety issue), Biogen (Aduhelm launch flop) and Incyte (biotech mid cap selloff).

Higher inflation and interest rates have ignited a sharp style reversion in the first few trading weeks of 2022. Large-cap-growth-at-any-price type of companies have sold off strongly while cheaper, less crowded healthcare value stocks have held up reasonably well. With a long list of macro worries, inflation, rates, supply chain disruptions, labour shortages etc., we think it makes sense to invest in stocks with large margin of safety from a valuation perspective. Large-cap growth/ thematic names still look expensive to us, but we do find attractive growth-oriented investments in the mid-cap segment of the healthcare space (select mid-cap biotech and proteomics names). The healthcare sector is flush with cash after the Covid-19 windfall profit from testing, vaccines, and therapeutics. We would expect this cashflow to be reinvested in M&A in 2022 and beyond, providing an important source of active money flow in the sector. Healthcare stocks are bifurcated in terms of valuations, hopefully creating an attractive stock picking environment going forward.

Harvest Equity Kernel

After a difficult year in 2020, the Investment Manager recommended to the Board of Directors to terminate the Fund in January 2021, and consequently the Fund was closed.

The investments underlying this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

Sector Gamma AS
January 2022

Deloitte.

Deloitte Ireland LLP
Chartered Accountants &
Statutory Audit Firm

INDEPENDENT AUDITOR'S REPORT TO THE SHAREHOLDERS OF SECTOR CAPITAL FUNDS PUBLIC LIMITED COMPANY

Report on the audit of the financial statements

Opinion on the financial statements of Sector Capital Funds Public Limited Company ("the company")

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2021 and of the profit for the financial year then ended; and
- have been properly prepared in accordance with the relevant financial reporting framework, the applicable Regulations and, in particular, with the requirements of the Companies Act 2014.

The financial statements we have audited comprise:

- the Profit and Loss Account;
- the Balance Sheet;
- the Schedule of Investments;
- the Statement of Net Assets attributable to holders of Redeemable Participating Shares; and
- the related notes 1 to 23, including a summary of significant accounting policies as set out in note 2.

The relevant financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' issued by the Financial Reporting Council ("the relevant financial reporting framework").

The applicable regulations that have been applied in their preparation is the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 and Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) (Undertakings for Collective Investment in Transferable Securities) Regulations, 2019 ("the applicable Regulations").

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are described below in the "*Auditor's responsibilities for the audit of the financial statements*" section of our report.

We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Ireland, including the Ethical Standard issued by the Irish Auditing and Accounting Supervisory Authority, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Continued on next page/

/Continued from previous page

INDEPENDENT AUDITOR’S REPORT TO THE SHAREHOLDERS OF
SECTOR CAPITAL FUNDS PUBLIC LIMITED COMPANY

Other information

The other information comprises the information included in the Annual Report and Audited Financial Statements, other than the financial statements and our auditor’s report thereon. The directors are responsible for the other information contained within the Annual Report and Audited Financial Statements. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Responsibilities of directors

As explained more fully in the Statement of Director's Responsibilities, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view and otherwise comply with the Companies Act 2014, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (Ireland), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company’s internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.

- Conclude on the appropriateness of the directors’ use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our

Continued on next page/

Deloitte.

/Continued from previous page

INDEPENDENT AUDITOR'S REPORT TO THE SHAREHOLDERS OF
SECTOR CAPITAL FUNDS PUBLIC LIMITED COMPANY

opinion. Our conclusions are based on the audit evidence obtained up to the date of the auditor's report. However, future events or conditions may cause the entity (or where relevant, the group) to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that the auditor identifies during the audit.

Report on other legal and regulatory requirements

Opinion on other matters prescribed by the Companies Act 2014

Based solely on the work undertaken in the course of the audit, we report that:

- We have obtained all the information and explanations which we consider necessary for the purposes of our audit.
- In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited.
- The financial statements are in agreement with the accounting records.
- In our opinion the information given in the directors' report is consistent with the financial statements and the directors' report has been prepared in accordance with the Companies Act 2014.

Matters on which we are required to report by exception

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report.

We have nothing to report in respect of the provisions in the Companies Act 2014 which require us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions specified by law are not made.

Use of our report

This report is made solely to the company's shareholders, as a body, in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's shareholders those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's shareholders as a body, for our audit work, for this report, or for the opinions we have formed.

Christian Macmanus
For and on behalf of Deloitte Ireland LLP
Chartered Accountants and Statutory Audit Firm
Deloitte & Touche House, 29 Earlsfort Terrace, Dublin 2

24 March 2022

BALANCE SHEET

As at 31 December 2021

	Note	Harvest Equity Kernel USD	Sector Healthcare Value Fund USD	Sector Capital Funds Plc USD
Current Assets				
Investments in financial assets held at fair value through profit or loss	7	–	483,115,725	483,115,725
Cash at bank and brokers	6	–	454,076	454,076
Subscriptions receivable		–	629,035	629,035
Interest receivable		–	73	73
Dividends receivable		–	926,744	926,744
Other assets		–	3,945	3,945
Total Assets		–	485,129,598	485,129,598
Current Liabilities				
Investments in financial liabilities held at fair value through profit or loss	7	–	625,568	625,568
Redemptions payable		–	422,516	422,516
Subscriptions received in advance		–	121,237	121,237
Payable to investment manager	9	–	391,047	391,047
Incentive fee/performance fee	10	–	199,820	199,820
Administration fee	11	–	91,600	91,600
Directors' fees and expenses	12	–	11,759	11,759
Auditors' fee		–	13,712	13,712
Depositary/Custodian fee	11	–	13,399	13,399
Legal fee		–	28,197	28,197
Equalisation credit payable		–	2,249,863	2,249,863
Trading and Research fees		–	12,000	12,000
Other creditors		–	64,130	64,130
Total Liabilities (excluding net assets attributable to holders of Redeemable Participating Shares)		–	4,244,848	4,244,848
Net assets attributable to holders of Redeemable Participating Shares	20	**–**	**480,884,750**	**480,884,750**

Harvest Equity Kernel ceased trading on 15 January 2021.

On behalf of the Board of Directors

DocuSigned by:
MJ Boyce
E1CF5842BDAF402...
Michael Boyce, Director

DocuSigned by:
Conor Walsh
60A8A95D67E74E3...
Conor Walsh, Director

Date: 22 March 2022

BALANCE SHEET (Continued)

As at 31 December 2020

	Note	Harvest Equity Kernel USD	Sector Healthcare Value Fund USD	Sector Capital Funds Plc USD
Current Assets				
Investments in financial assets held at fair value through profit or loss	7	109,556,088	368,441,456	477,997,544
Cash at bank and brokers	6	15,847,914	5,970,273	21,818,187
Interest receivable		36	69	105
Dividends receivable		45,965	660,180	706,145
Other assets		1,265	1,033	2,298
Total Assets		125,451,268	375,073,011	500,524,279
Current Liabilities				
Investments in financial liabilities held at fair value through profit or loss	7	301,921	937,236	1,239,157
Payable for securities purchased		–	2,282,642	2,282,642
Subscriptions received in advance		52,382	573,228	625,610
Payable to investment manager	9	178,612	311,463	490,075
Incentive fee/performance fee	10	–	317,753	317,753
Administration fee	11	57,895	72,257	130,152
Directors' fees and expenses	12	5,468	9,174	14,642
Auditors' fee		12,029	13,553	25,582
Depositary/Custodian fee	11	8,914	15,987	24,901
Legal fee		7,547	4,240	11,787
Interest payable		4,091	–	4,091
Equalisation credit payable		–	3,183,406	3,183,406
Trading and Research fees		120,191	13,999	134,190
Other creditors		9,749	28,211	37,960
Total Liabilities (excluding net assets attributable to holders of Redeemable Participating Shares)		758,799	7,763,149	8,521,948
Net assets attributable to holders of Redeemable Participating Shares	20	**124,692,469**	**367,309,862**	**492,002,331**

PROFIT AND LOSS ACCOUNT

For the financial year ended 31 December 2021

	Note	Harvest Equity Kernel USD	Sector Healthcare Value Fund USD	Sector Capital Funds Plc USD
Income				
Dividend income		74,355	9,046,086	9,120,441
Interest income		3,016	953	3,969
Other income		5,607	35,302	40,909
		82,978	9,082,341	9,165,319
Net realised gain/(loss) on:				
- investments		25,027,418	49,081,573	74,108,991
- foreign currency		3,299,070	(2,073,615)	1,225,455
Net change in unrealised appreciation/(depreciation) on:				
- investments		(21,230,244)	(3,054,396)	(24,284,640)
- foreign currency		(3,259,718)	(10,922,673)	(14,182,391)
Net investment gain		**3,919,504**	**42,113,230**	**46,032,734**
Expenses				
Management fee	9	(27,604)	(4,542,612)	(4,570,216)
Incentive fee/performance fee	10	–	102,056	102,056
Administration fee	11	1,755	(492,926)	(491,171)
Depositary/Custodian fee	11	(6,812)	(172,204)	(179,016)
Directors' fees and expenses	12	–	(38,188)	(38,188)
Auditors' fee		(8,455)	(13,583)	(22,038)
Legal fee		–	(123,183)	(123,183)
Listing fee		(1,266)	–	(1,266)
Trading and research fees		–	(115,529)	(115,529)
Other expenses		(28,961)	(184,244)	(213,205)
Total expenses		(71,343)	(5,580,413)	(5,651,756)
Net gain before finance costs		**3,848,161**	**36,532,817**	**40,380,978**
Finance costs				
Interest expense		(20,050)	(5,402)	(25,452)
Total finance costs		**(20,050)**	**(5,402)**	**(25,452)**
Taxation				
Withholding tax and other taxation		(20,928)	(1,642,853)	(1,663,781)
Net increase in net assets attributable to holders of Redeemable Participating Shares resulting from operations		**3,807,183**	**34,884,562**	**38,691,745**

There are no recognised gains or losses for the year other than those set out in the Profit and Loss Account. All activities relate to continuing operations except for Harvest Equity Kernel, which ceased trading on 15 January 2021.

PROFIT AND LOSS ACCOUNT (Continued)

For the financial year ended 31 December 2020

	Note	Harvest Equity Kernel USD	Sector Healthcare Value Fund USD	Sector Capital Funds Plc USD
Income				
Dividend income		2,390,275	3,876,579	6,266,854
Interest income		58,430	38,817	97,247
Other income		5,797	279,348	285,145
		2,454,502	4,194,744	6,649,246
Net realised gain/(loss) on:				
- investments		8,262,174	17,645,325	25,907,499
- foreign currency		558,951	9,542,865	10,101,816
Net change in unrealised appreciation/(depreciation) on:				
- investments		2,536,448	(1,739,586)	796,862
- foreign currency		1,748,548	8,236,999	9,985,547
Net investment gain		**15,560,623**	**37,880,347**	**53,440,970**
Expenses				
Management fee	9	(751,154)	(2,723,228)	(3,474,382)
Incentive fee/performance fee	10	–	239,439	239,439
Administration fee	11	(208,146)	(312,469)	(520,615)
Depositary/Custodian fee	11	(75,928)	(105,814)	(181,742)
Directors' fees and expenses	12	(12,727)	(21,806)	(34,533)
Auditors' fee		(9,571)	(11,064)	(20,635)
Legal fee		(32,727)	(83,019)	(115,746)
Listing fee		(4,971)	(5,383)	(10,354)
Trading and research fees		(360,000)	(67,264)	(427,264)
Other expenses		(77,499)	(129,863)	(207,362)
Total expenses		(1,532,723)	(3,220,471)	(4,753,194)
Net gain before finance costs		**14,027,900**	**34,659,876**	**48,687,776**
Finance costs				
Interest expense		(135,240)	(5,376)	(140,616)
Total finance costs		**(135,240)**	**(5,376)**	**(140,616)**
Taxation				
Withholding tax and other taxation		(454,754)	(719,855)	(1,174,609)
Net increase in net assets attributable to holders of Redeemable Participating Shares resulting from operations		**13,437,906**	**33,934,645**	**47,372,551**

There are no recognised gains or losses for the year other than those set out in the Profit and Loss Account. All activities relate to continuing operations.

STATEMENT OF NET ASSETS ATTRIBUTABLE TO HOLDERS OF REDEEMABLE PARTICIPATING SHARES

For the financial year ended 31 December 2021

	Harvest Equity Kernel USD	Sector Healthcare Value Fund USD	Sector Capital Funds Plc USD
Net Assets attributable to holders of Redeemable Participating Shares at beginning of the financial year	**124,692,469**	**367,309,862**	**492,002,331**
Capital transactions:			
Issue of Redeemable Participating Shares	629,011	150,653,709	151,282,720
Redemption of Redeemable Participating Shares	(129,128,663)	(72,066,426)	(201,195,089)
Equalisation applied	–	103,043	103,043
Net (decrease)/increase in net assets resulting from capital transactions of Redeemable Participating Shares	**(128,499,652)**	**78,690,326**	**(49,809,326)**
Net increase in net assets attributable to holders of Redeemable Participating Shares resulting from operations	**3,807,183**	**34,884,562**	**38,691,745**
Net Assets attributable to holders of Redeemable Participating Shares at end of the financial year	**–**	**480,884,750**	**480,884,750**

The accompanying notes form an integral part of the financial statements

STATEMENT OF NET ASSETS ATTRIBUTABLE TO HOLDERS OF REDEEMABLE PARTICIPATING SHARES (Continued)

For the financial year ended 31 December 2020

	Harvest Equity Kernel USD	Sector Healthcare Value Fund USD	Sector Capital Funds Plc USD
Net Assets attributable to holders of Redeemable Participating Shares at beginning of the financial year	**127,320,414**	**167,225,950**	**294,546,364**
Capital transactions:			
Issue of Redeemable Participating Shares	42,226,070	236,175,465	278,401,535
Redemption of Redeemable Participating Shares	(58,291,921)	(68,800,525)	(127,092,446)
Equalisation applied	–	(1,225,673)	(1,225,673)
Net (decrease)/increase in net assets resulting from capital transactions of Redeemable Participating Shares	**(16,065,851)**	**166,149,267**	**150,083,416**
Net increase in net assets attributable to holders of Redeemable Participating Shares resulting from operations	**13,437,906**	**33,934,645**	**47,372,551**
Net Assets attributable to holders of Redeemable Participating Shares at end of the financial year	**124,692,469**	**367,309,862**	**492,002,331**

SCHEDULE OF INVESTMENTS

As at 31 December 2021

Sector Healthcare Value Fund

Investment	Units/Contracts	Fair Value as a % of Net Assets	Fair Value USD
Financial Assets at Fair Value through profit or loss			
Equities			
Belgium			
UCB S.A.	85,650	2.03%	9,774,208
Total Belgium		2.03%	9,774,208
Denmark			
H Lundbeck A/S	337,642	1.81%	8,716,922
Total Denmark		1.81%	8,716,922
France			
BioMerieux	34,638	1.03%	4,919,853
Sanofi	286,558	6.00%	28,865,897
Total France		7.03%	33,785,750
Germany			
BioNTech SE	9,491	0.51%	2,446,780
Evonik Industries AG	156,162	1.05%	5,055,914
Total Germany		1.56%	7,502,694
Ireland			
Medtronic Plc	163,821	3.53%	16,947,283
Total Ireland		3.53%	16,947,283
Japan			
Eisai Co. Ltd.	71,568	0.84%	4,058,969
Miraca Holdings, Inc.	30,000	0.16%	760,714
Otsuka Holdings Co. Ltd.	214,083	1.61%	7,750,528
Shimadzu Corp.	111,495	0.98%	4,700,692
Total Japan		3.59%	17,270,903
Netherlands			
Koninklijke Philips NV	186,676	1.45%	6,955,614
Qiagen NV	148,503	1.71%	8,253,797
Total Netherlands		3.16%	15,209,411
Switzerland			
Novartis AG	238,595	4.37%	21,022,232
Total Switzerland		4.37%	21,022,232
United Kingdom			
ConvaTec Group Plc	934,800	0.51%	2,445,549
GlaxoSmithKline Plc	1,767,458	8.00%	38,460,936
Smith & Nephew Plc	578,915	2.11%	10,142,481
Total United Kingdom		10.62%	51,048,966
United States			
Anthem, Inc.	24,756	2.39%	11,475,396
Becton Dickinson & Co.	59,503	3.11%	14,963,814
Biogen, Inc.	47,579	2.38%	11,415,154
BioMarin Pharmaceutical, Inc.	76,325	1.40%	6,743,314
Bio-Rad Laboratories, Inc.	7,469	1.17%	5,643,352
Boston Scientific Corp.	378,436	3.34%	16,075,961
Bristol-Myers Squibb Co.	265,202	3.44%	16,535,345
Bruker Corp.	108,717	1.90%	9,122,443
Cardinal Health, Inc.	339,807	3.64%	17,496,662
Centene Corp.	130,015	2.23%	10,713,236
Cigna Corp.	32,954	1.57%	7,567,227
CVS Health Corp.	143,952	3.09%	14,850,088
Dentsply Sirona, Inc.	101,016	1.17%	5,635,683
Elanco Animal Health, Inc.	237,233	1.40%	6,732,672
Gilead Sciences, Inc.	205,808	3.11%	14,943,719
Incyte Corp. Ltd.	272,710	4.16%	20,016,914
Ionis Pharmaceuticals, Inc.	154,595	0.98%	4,704,326
Laboratory Corporations of America Holdings	19,797	1.29%	6,220,415

SCHEDULE OF INVESTMENTS (Continued)
As at 31 December 2021

Sector Healthcare Value Fund (Continued)

Investment	Units/Contracts	Fair Value as a % of Net Assets	Fair Value USD
Financial Assets at Fair Value through profit or loss (continued)			
Equities (continued)			
United States (continued)			
Merck & Co., Inc.	363,722	5.80%	27,875,654
Mirati Therapeutics, Inc.	18,933	0.58%	2,777,282
Novavax, Inc.	8,751	0.26%	1,252,006
NuVasive, Inc.	178,779	1.95%	9,382,322
Organon & Co.	316,177	2.00%	9,627,590
Patterson Cos., Inc.	83,714	0.51%	2,457,006
Pfizer, Inc.	259,258	3.18%	15,309,185
Rigel Pharmaceuticals, Inc.	846,651	0.47%	2,243,625
Sage Therapeutics, Inc.	70,235	0.62%	2,987,797
Universal Health Services, Inc.	31,936	0.86%	4,140,822
Vertex Pharmaceuticals, Inc.	32,208	1.47%	7,072,877
Vir Biotechnology, Inc.	29,110	0.25%	1,218,836
Total United States		59.72%	287,200,723
Total Equities		**97.42%**	**468,479,092**
Money Market Funds			
Goldman Sachs US$ Treasury Liquid Reserves Fund	10,205,237	2.12%	10,205,237
Total Money Market Funds		**2.12%**	**10,205,237**
Net unrealised gain on forward foreign currency contracts (Note 7)		0.92%	4,431,396
Total Financial Assets at Fair Value through profit or loss		**100.46%**	**483,115,725**
Financial Liabilities at Fair Value through profit or loss			
Net unrealised loss on forward foreign currency contracts (Note 7)		(0.13)%	(625,568)
Total Financial Liabilities at Fair Value through profit or loss		**(0.13)%**	**(625,568)**
Total Investments at Fair Value		**100.33%**	**482,490,157**
Cash at bank and brokers		0.09%	454,076
Liabilities in excess of other assets		(0.42)%	(2,059,483)
Total Net Assets		**100.00%**	**480,884,750**

ALL SECURITIES ARE TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL EXCHANGE LISTING OR TRADED ON A REGULATED MARKET EXCEPT FOR FORWARD FOREIGN CURRENCY CONTRACTS WHICH ARE FINANCIAL DERIVATIVE INSTRUMENTS

Analysis of Total Assets	% of Total Assets
Transferable securities admitted to an official exchange listing or traded on a regulated market	98.67%
Financial derivative instruments	0.91%
Other assets	0.42%
Total Assets	**100.00%**

NOTES TO THE FINANCIAL STATEMENTS

1. Organisation and Structure

Sector Capital Funds plc (the "Company") was incorporated and registered in Ireland with registered number 489443 and is governed by the Companies Acts 2014 as an open-ended umbrella investment company with variable capital and with segregated liability between sub-funds on 27 September 2010. The Company is authorised by the Central Bank of Ireland pursuant to European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48 (1) (Undertakings for Collective Investment in Transferable Securities) Regulations, 2019 (the "Regulations").

As at 31 December 2021, the Company has two funds in existence (31 December 2020: three), Sector Healthcare Value Fund and Harvest Equity Kernel (formerly Sector Global Equity Kernel). Harvest Equity Kernel ceased trading effective 15 January 2021. Effective 21 May 2021, Sector Sigma Nordic Fund's authorisation was revoked by the Central Bank of Ireland. An application will be made to the Central Bank of Ireland to Harvest Equity Kernel's authorisation revoked.

Sector Healthcare Value Fund commenced trading on 17 November 2010. The base currency of Sector Healthcare Value Fund is United States Dollars ("USD"). As at 31 December 2021, fourteen classes are subscribed to in the Fund (31 December 2020: twelve), Class A EUR Shares, Class A NOK Shares, Class A USD Shares, Class B EUR Shares, Class B NOK Shares, Class B SEK Shares, Class B USD Shares, Class X USD Shares, Class X EUR Shares, Class Y EUR Shares, Class Y GBP Shares, Class Y USD Shares, Class E NOK and Class E USD.

Harvest Equity Kernel commenced trading on 19 March 2014. The base currency of Harvest Equity Kernel was USD. Effective 2 January 2020, the Fund changed its name from Sector Global Equity Kernel to Harvest Equity Kernel. As at 15 January 2021, the Fund ceased operations.

Investment Objective

The investment objective of Sector Healthcare Value Fund is to achieve attractive long term investment returns relative to the MSCI Daily TR World Net Health Care USD (the "Index"). The Index is a capitalisation weighted index that monitors the performance of health care stocks from around the world. The Fund may invest in equities and financial instruments that are not part of the Index. There can be no guarantee that the investment objective of the Fund will be achieved.

The investment objective of Harvest Equity Kernel was to maximise long-term total return relative to MSCI ACWI Index (the "Index"). The Index is a free float-adjusted market capitalisation weighted index that is designed to measure the equity market performance of developed and emerging markets. The MSCI ACWI consists of 45 country indices comprising 24 developed and 21 emerging market country indices. There was no guarantee that the investment objective of the Fund would be achieved.

2. Summary of Significant Accounting Policies

The financial statements have been prepared in accordance with Financial Reporting Standard 102 ("FRS 102"), the Financial Reporting Standard applicable in the UK and Republic of Ireland, the Companies Acts 2014, the Regulations.

The financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets and financial liabilities at fair value through profit or loss in accordance with the European Communities (Fair Value Accounting) Regulations 2011.

The Company has availed of certain exemptions available to open-ended investment funds in FRS 102 not to prepare a cash flow statement in paragraph 7.1A of FRS 102.

The preparation of financial statements in accordance with FRS 102 requires Directors to make judgements, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the financial year. Actual results could differ from those estimates.

NOTES TO THE FINANCIAL STATEMENTS (Continued)

2. Summary of Significant Accounting Policies (Continued)

The financial statements of the Company have been prepared on a going concern basis. The Company is able to meet all of its liabilities from its assets. The performance, marketability and risks of the Company are reviewed on a regular basis throughout the financial year. Therefore, the Directors believe that the Company will continue in operational existence for the foreseeable future and is financially sound. The Directors are satisfied that, at the time of approving the financial statements, it is appropriate to adopt the going concern basis in preparing the financial statements of the Company.

(a) Portfolio valuation

Investment transactions

(i) Classification
The Company classifies all of its investments as financial assets or financial liabilities at fair value through profit or loss. These financial instruments are designated on the basis that their fair value can be reliably measured and their performance has been evaluated on a fair value basis in accordance with the risk management and/or investment strategy as set out in the Company's Prospectus.

(ii) Recognition
The Company recognises financial assets and financial liabilities on the date it becomes party to the contractual provisions of the instrument. Investment transactions are accounted for on a trade date basis at cost. Purchases and sales of securities are accounted for on the trade date on which the transaction takes place. Transaction costs are expensed immediately to the Profit and Loss Account and not capitalised as part of cost of the investment.

(iii) Measurement
Financial assets and financial liabilities held for trading are measured at fair value. Fair value is the amount for which an asset could be exchanged, or a liability settled, between knowledgeable, willing parties in an arm's length transaction.

Realised gains and losses on sales of investments are calculated on a First-In, First-Out ("FIFO") basis. Unrealised gains and losses on investments are recognised in the Profit and Loss Account. Forward foreign currency contracts and any other instruments held by the Company and traded on an exchange will be measured at fair value based on the last reported traded price on such regulated market as at the relevant valuation point.

If an investment is quoted, listed or normally dealt in on more than one market, the Directors may, in their absolute discretion, select any of such markets for the valuation purposes.

(iv) Derecognition
The Company derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire or it transfers the financial asset and the transfer qualifies for derecognition.

A financial liability is derecognised when the obligation specified in the contract is discharged, cancelled or expired.

(b) Forward foreign currency contracts

The unrealised gain or loss on open forward foreign currency contracts is calculated by reference to the difference between the contracted rate and the rate to close out the contract. Realised gains or losses include net gains on contracts which have been settled or offset by other contracts.

(c) Foreign exchange translation

Items included in the Company's financial statements are measured using the currency of the primary economic environment in which it operates (the "functional currency"). The functional currency of Harvest Equity Kernel was the United States Dollar ("USD"), due to the fact that the majority of the Fund's assets were denominated in USD. The functional currency of Sector Healthcare Value Fund is the United States Dollar ("USD"), due to the fact that the majority of the Fund's assets are denominated in USD and that a substantial portion of capital is issued in USD. Each Fund has adopted its functional currency as the presentation currency for these financial statements. Assets and liabilities expressed in foreign currencies are converted into the functional currency of each Fund using the exchange rates prevailing as at the balance sheet date. Transactions in foreign currencies are translated into the Fund's functional currency at exchange rates ruling at the transaction dates. Gains and losses on foreign exchange transactions are recognised in the Profit and Loss Account in determining the result for the year.

(d) Offsetting financial instruments

Financial assets and financial liabilities may be offset and the net amount reported in the Balance Sheet when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis, or realise the asset and settle the liability simultaneously. As at 31 December 2021 and 31 December 2020, no offsetting has been presented in the Balance Sheet.

NOTES TO THE FINANCIAL STATEMENTS (Continued)

2. Summary of Significant Accounting Policies (Continued)

(e) Income

Dividends are recognised as income on the dates that securities are first quoted "ex-dividend" to the extent information thereon is reasonably available to the Company. Interest income is accrued on a daily basis. Deposit interest is recognised as income on an accruals basis.

(f) Expenses

Operating expenses are accounted for on an accruals basis.

(g) Net asset value per share

The Net Asset Value per Share of each class is calculated by dividing the Net Asset Value attributable to a class by the number of shares of a class in issue as at the relevant valuation point.

(h) Redeemable participating shares

Shares issued by each Fund provide shareholders with the right to redeem their shares, for cash equal to their proportional share of the net asset value of the Fund and are classified as financial liabilities in accordance with FRS 102. The Fund does not meet the requirement to be classified as equity as the Fund offers different classes of shares with varying rights attached to them. The liabilities to shareholders are presented on the Balance Sheet as "Net assets attributable to holders of Redeemable Participating Shares" and are determined based on the residual assets of the Fund after deducting the Fund's other liabilities.

(i) Amounts due from/to broker

Amounts due from/to broker relate to the outstanding amounts pending settlement on forward foreign currency contracts and upfront cash payments for fully funded contracts-for-difference.

(j) Taxation

The Company incurs dividend withholding tax and other taxation imposed by certain countries on investment income and gains on investments. Dividend income is shown gross of any non-recoverable withholding taxes, which are disclosed separately in Profit and Loss Account.

(k) Transaction costs

Transaction costs are costs incurred to acquire financial assets or financial liabilities at fair value through profit or loss. They include fees and commissions paid to agents, advisers, brokers and dealers. Transaction costs, when incurred, are immediately recognised in profit or loss as an expense. For the financial year ended 31 December 2021 Harvest Equity Kernel incurred transaction costs of USD86,854 (31 December 2020: USD132,002), Sector Healthcare Value Fund incurred transaction costs of USD267,541 (31 December 2020: USD236,479).

(l) Cash

Cash at bank and brokers represents, cash and cash equivalents, with original maturities of three months or less held with the Depositary and brokers.

3. Dividend and Distribution Policy

The Directors do not currently intend to pay dividends. Accordingly, the price of the shares shall rise as income and capital gains accrue.

4. Taxation

The Company will not be liable to tax in respect of its income and gains, other than on the occurrence of a chargeable event. Generally a chargeable event arises on any distribution, redemption, repurchase, cancellation, transfer of shares or on the ending of a 'Relevant Year', a 'Relevant Year' being an eight year period beginning with the acquisition of the shares by the shareholders and each subsequent year of eight years beginning immediately after the preceding relevant year.

A chargeable event does not include:

(i) Any transactions in relation to shares held in a recognised clearing system: or
(ii) An exchange of shares representing a fund for another fund: or
(iii) An exchange of shares arising on a qualifying amalgamation or reconstruction of a Fund with another fund: or
(iv) Certain exchanges of shares between spouses and former spouses.

A chargeable event will not occur in respect of shareholders who are neither resident nor ordinarily resident in Ireland and who have provided the Company with a relevant declaration to that effect.

NOTES TO THE FINANCIAL STATEMENTS (Continued)

4. Taxation (Continued)

In the absence of an appropriate declaration, the Company will be liable to Irish Tax on the occurrence of a chargeable event. There were no chargeable events during the year under review. Capital gains, dividends and interest received may be subject to withholding taxes imposed by the country of origin and such taxes may not be recoverable by the Company or its shareholders.

5. Exchange Rates

The following exchange rates (against USD) were used to convert the investments and other assets and liabilities denominated in currencies other than USD as at 31 December 2021 and 31 December 2020:

Currency	31 December 2021	31 December 2020
Australian Dollar	-	1.2959
Brazilian Real	-	5.1943
British Pound	0.7383	0.7316
Canadian Dollar	-	1.2740
Chinese Renminbi	-	6.5398
Danish Krone	6.5403	6.0835
Euro	0.8794	0.8173
Hong Kong Dollar	-	7.7539
Hungarian Forint	324.1491	296.3841
Indian Rupee	-	73.0460
Japanese Yen	115.1543	103.2418
Korean Won	-	1,085.7763
Norwegian Krone	8.8183	8.5619
Singapore Dollar	-	1.3216
Swedish Krona	9.0539	8.2125
Swiss Franc	0.9112	0.8839
Taiwan Dollar	-	28.0978
Thailand Baht	-	29.9599
Turkish Lira	-	7.4325

6. Cash

As at 31 December 2021 and 31 December 2020 all cash balances (including overdrafts) are held with The Bank of New York Mellon SA/NV, Dublin Branch (the "Depositary"), DNB and Goldman Sachs.

31 December 2021	Harvest Equity Kernel USD	Sector Healthcare Value Fund USD
BNY Mellon	-	454,076
	-	**454,076**

31 December 2020	Harvest Equity Kernel USD	Sector Healthcare Value Fund USD
BNY Mellon	3,304,915	5,970,273
DNB	10,125,404	-
Goldman Sachs	2,417,595	-
	15,847,914	**5,970,273**

As at 31 December 2021, Harvest Equity Kernel pledged USDNil as collateral with Goldman Sachs (31 December 2020: USD2,180,000). Any overdrafts noted above are temporary in nature as they relate to timing differences only.

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks

Included in the Company's financial instruments, but not limited to, are global equities and equity related securities (including but not limited to American Depositary Receipts, Global Depositary Receipts, European Depositary Receipts and other equity based derivatives), corporate bonds and government debt obligations that shall be listed or traded on any market.

The main risks arising from the Company's financial instruments are market price, liquidity, interest rate, foreign currency and credit risks.

The Market Risk Group ("MRG") functions across all Sector Investment Manager entities and the group is responsible for defining risk management related limits ("soft limits") in addition to the investment restrictions found in the Prospectus and related supplements, in cooperation with the respective Investment Manager, securing that the Funds have a portfolio construction and risk exposure that are in line with the intentions of the individual Funds. The limits are generally related to exposure towards single positions and sectors, total portfolio exposure and Value-at-Risk ("VAR"). MRG consists of the CEO of Sector Asset Management AS (leader of MRG), Head of Fund Operations, the CCO and CEO of Sector Fund Services AS. The Head of Fund Operations has the mandate to give short term exceptions to the risk limits set by MRG if he/she finds that under certain market conditions, the limits have unintended adverse effects, for example in extreme market conditions. Such exceptions are reported to the other members of MRG and to the Group Chief Compliance Officer.

(a) Market price risk

Market price risk arises from uncertainty concerning future prices of financial instruments. The consequence might be a decline in the Fund's value. The risk related to the Funds – i.e. a combination of the probability of loss and the consequences – must be weighed against the potential gain for the Fund. To limit the risk, the Funds are both diversified and constructed through fundamental analyses of the expected behaviour and volatility of the individual instruments while following each Fund's investment objective.

Value-at-Risk

Value-at-Risk (VaR) represents the potential loss one might suffer given a defined confidence interval and time horizon. The measure is one of the main risk measures for the Company under normal market conditions.

One of the key metrics used by the Sector Group to measure market risk is VAR which encompasses currency, interest rate and price risk.

The main risk management tool for VaR calculations was Bloomberg. For all Funds, the Bloomberg VaR calculation is based on Monte Carlo simulations at a 95% confidence interval i.e. that one in every 20 days is expected to be above this measure in the long run.

For the financial year ended 31 December 2021

	Period end VaR	Gross Exposure*	Net Exposure**	lowest VaR	highest VaR	average VaR
Sector Healthcare Value Fund	1.54%	97.4%	97.4%	1.52%	2.29%	1.83%

For the financial year ended 31 December 2020

	Period end VaR	Gross Exposure*	Net Exposure**	lowest VaR	highest VaR	average VaR
Harvest Equity Kernel	1.61%	87.2%	87.2%	1.61%	2.07%	1.86%
Sector Healthcare Value Fund	2.25%	94.5%	94.5%	2.25%	2.73%	2.44%

* Exposure as % of NAV
** Net open position as % of NAV

Exposure

Exposure for pure equities is equal to the fair value of the securities. The total gross exposure of each Fund is the sum of the absolute values of all long and short exposures.

(b) Interest rate risk

Interest rate risk is the risk (variability in value) borne by an interest-bearing asset, due to variability of interest rates. In general, as rates rise, the price of a fixed rate bond will fall, and vice versa. Interest rate risk is commonly measured by the bond's duration. For the financial year ended 31 December 2021 and 31 December 2020 the Funds, have not invested in interest bearing assets, other than cash amounts. As at 31 December 2021 and 31 December 2020, the Funds do not have any significant fair value interest rate risk exposure.

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(b) Interest rate risk (Continued)

Tables outlining the currency and interest exposure as at 31 December 2021 and 31 December 2020 are outlined in note 7(d).

(c) Liquidity risk

Liquidity risk is linked to the Funds having to realise assets in unfavourable market conditions with large losses as a consequence due to for example, redemptions in a Fund or a collapse in long asset values reducing the collateral held by counterparties leading to margin calls, if applicable. This means that there are two aspects that are monitored; what is the probability of the situation occurring and how fast can the Funds realise their positions without significant adverse effects on the value of the positions.

Liquidity of portfolio

The Company's Prospectus provides for daily subscription and redemption of shares in the Funds, therefore the Funds are exposed to a liquidity risk of meeting shareholder redemptions on a daily basis. The majority of the Funds' assets are comprised of publicly traded securities and are thus relatively easily realised. Still, with each Fund having the possibility to take positions in small cap equities, the ability of a Fund to realise assets within a short period of time without a large negative impact on the value of the assets is important. Some of the recognised exchanges on which a Fund may invest may prove to be less liquid or highly volatile from time to time. The Funds may invest a limited proportion of their assets in unquoted securities.

For the financial year ended 31 December 2021 and 31 December 2020, the Funds held very liquid assets and liquidity was monitored daily by the Investment Managers.

The reports below are snapshots of the estimated liquidity of the Funds as at 31 December 2021 and 31 December 2020:

31 December 2021

Sector Healthcare Value Fund

Description	Cumulative
< 1 day	94.9%
1-2 days	98.7%
3-5 days	100%

31 December 2020

Harvest Equity Kernel		Sector Healthcare Value Fund	
Description	**Cumulative**	**Description**	**Cumulative**
< 1 day	99.2%	< 1 day	99.8%
1-2 days	100%	1-2 days	100%
3-5 days	100%	3-5 days	100%

(d) Foreign currency risk

Foreign currency risk is in reality a sub-group of market risk, but with its own idiosyncrasies, both with respect to a Fund's portfolio as well as the investor classes denominated in different currencies. Certain currency related transactions may, for example, be employed by the Funds in order to hedge against foreign exchange risk subject to the conditions and limits laid down by the Central Bank of Ireland. Such transactions include forward foreign currency contracts and may for example be executed in cases where an investment is in a currency other than the Fund's functional currency.

A substantial portion of the financial assets of the Funds are denominated in currencies other than the relevant Fund's functional currency with the effect that the balance sheet of the Funds can be significantly affected by currency movements.

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(d) Foreign currency risk (Continued)

Currency exposure for investor classes

The shares of the Company are denominated in United States Dollar (USD), Euro (EUR), Norwegian Krone (NOK), British Pound (GBP) and Swedish Krona (SEK) and are issued and redeemed in those currencies. The Investment Manager may seek to hedge the foreign currency exposure of the assets attributable to the shares in order to neutralise as far as reasonably possible, the impact of fluctuations in exchange rates. This is done monthly in addition to when a Fund has more than 3% absolute return, month to date. There is no guarantee that such hedging will give returns that are equal regardless of which currency the shareholders have invested in. In addition, shareholders whose assets and liabilities are predominantly in currencies other than the currency of investment in the Company should take into account the potential risk of loss arising from fluctuations in value between USD, EUR, NOK, GBP or SEK being the currency of shareholder investment, and such other currencies as invested in by the Company.

Portfolio currency exposure

The Funds trade in many different markets across the world and in many different currencies. Thus, certain assets in the portfolio may, regardless of the shares of the Fund, be invested in securities which are denominated in currencies other than USD, EUR, NOK, GBP or SEK. Consequently, the value of such assets will be affected either favourably or unfavourably by fluctuations in currency rates. The exposure towards the different currencies based on the denomination of the securities is reported daily for each Fund. For each individual Fund, action towards currency exposure in the portfolio is taken by the Investment Manager based on reported exposure of the Fund's assets.

Amounts represented below primarily are monetary assets and monetary liabilities except for investments in non-interest bearing securities, which include equities and contracts-for-difference, which are non-monetary assets.

The foreign currency exposure as at 31 December 2021 is as follows:

Sector Healthcare Value Fund	Cash at Bank and Brokers	Forward Currency Contracts	Investments in Interest Bearing Assets	Investments in Non-Interest Bearing Assets	Investments in Non-Interest Bearing Liabilities	Net Other Assets/ (Liabilities)	Total Net Asset Value
Currency	**USD**	**USD**	**USD**	**USD**	**USD**	**USD**	**USD**
CHF	(915)	–	–	21,022,232	–	–	21,021,317
DKK	110	–	–	8,716,922	–	–	8,717,032
EUR	29,893	252,718	–	55,571,486	–	–	55,854,097
GBP	22,690	–	–	51,048,966	–	482,932	51,554,588
JPY	50	–	–	17,270,903	–	78,718	17,349,671
NOK	33,853	3,531,576	–	–	–	–	3,565,429
SEK	4,796	21,534	–	–	–	–	26,330
USD	363,599	–	–	325,053,820	–	(2,621,133)	322,796,286
Total	**454,076**	**3,805,828**	**–**	**478,684,329**	**–**	**(2,059,483)**	**480,884,750**

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(d) Foreign currency risk (Continued)

The foreign currency exposure as at 31 December 2020 is as follows:

Harvest Equity Kernel	Cash at Bank and Brokers	Forward Currency Contracts	Investments in Interest Bearing Assets	Investments in Non-Interest Bearing Assets	Investments in Non-Interest Bearing Liabilities	Net Other Assets/ (Liabilities)	Total Net Asset Value
Currency	**USD**	**USD**	**USD**	**USD**	**USD**	**USD**	**USD**
AUD	–	(9,322)	–	9,249,890	–	–	9,240,568
BRL	55	–	–	–	–	4,384	4,439
CAD	16,179	122,492	–	9,103,347	–	–	9,242,018
CHF	17,348	66,198	–	6,309,576	–	–	6,393,122
CNY	–	(29,292)	–	264,976	(130,389)	–	105,295
DKK	136	–	–	–	–	–	136
EUR	6,479	121,940	–	16,206,265	–	–	16,334,684
GBP	13,813	83	–	841,975	–	15,832	871,703
HKD	596,875	566	–	3,779,368	–	–	4,376,809
INR	–	(8,798)	–	–	(91,335)	–	(100,133)
JPY	(81)	142,779	–	14,426,279	–	–	14,568,977
KRW	–	(4,045)	–	1,819,387	–	6,202	1,821,544
NOK	232,366	690,240	–	–	–	–	922,606
SEK	12,475	(11,078)	–	2,133,725	–	–	2,135,122
SGD	444	–	–	–	–	–	444
THB	28	–	–	–	–	–	28
TRY	2	–	–	–	–	–	2
TWD	–	22,933	–	4,708,841	–	7,099	4,738,873
USD	14,951,795	–	–	39,527,566	–	(443,129)	54,036,232
Total	**15,847,914**	**1,104,696**	**–**	**108,371,195**	**(221,724)**	**(409,612)**	**124,692,469**

Sector Healthcare Value Fund	Cash at Bank and Brokers	Forward Currency Contracts	Investments in Interest Bearing Assets	Investments in Non-Interest Bearing Assets	Investments in Non-Interest Bearing Liabilities	Net Other Assets/ (Liabilities)	Total Net Asset Value
Currency	**USD**	**USD**	**USD**	**USD**	**USD**	**USD**	**USD**
CHF	539	–	–	–	–	–	539
DKK	155	–	–	2,090,780	–	–	2,090,935
EUR	19,518	1,164,649	–	48,592,018	–	–	49,776,185
GBP	21,706	1,519,477	–	34,472,084	–	344,340	36,357,607
JPY	3	–	–	15,681,348	–	33,521	15,714,872
NOK	10,487	3,648,559	–	–	–	–	3,659,046
SEK	7,326	98,754	–	–	–	–	106,080
USD	5,910,539	–	–	260,236,550	–	(6,542,492)	259,604,597
Total	**5,970,273**	**6,431,440**	**–**	**361,072,780**	**–**	**(6,164,631)**	**367,309,862**

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(d) Foreign currency risk (Continued)

As at 31 December 2021 the following forward foreign currency contracts were held by Sector Healthcare Value Fund.

Sector Healthcare Value Fund

Maturity Date	Counterparty	Sale Currency	Amount	Purchase Currency	Amount	Unrealised gain/(loss) USD
02 January 2022	BNY Mellon	SEK	(650,809)	USD	71,917	17
02 January 2022	BNY Mellon	USD	(7,730,892)	EUR	6,833,195	44,769
02 January 2022	BNY Mellon	USD	(460,355)	EUR	406,899	2,665
02 January 2022	BNY Mellon	USD	(38,823,877)	EUR	34,315,718	224,826
02 January 2022	BNY Mellon	USD	(27,496,525)	NOK	242,939,800	37,051
02 January 2022	BNY Mellon	USD	(91,049,996)	NOK	804,453,214	122,689
02 January 2022	BNY Mellon	USD	(3,689,387)	NOK	32,596,808	4,971
02 January 2022	BNY Mellon	USD	(179,977)	NOK	1,585,093	(331)
02 January 2022	BNY Mellon	USD	(11,519)	NOK	101,541	(11)
02 January 2022	BNY Mellon	USD	(3,000,732)	SEK	27,171,947	1,188
01 March 2022	BNY Mellon	EUR	(265,955)	USD	300,766	(1,696)
01 March 2022	BNY Mellon	EUR	(11,877)	USD	13,432	(75)
01 March 2022	BNY Mellon	EUR	(1,152,095)	USD	1,302,892	(7,347)
01 March 2022	BNY Mellon	EUR	(6,833,195)	USD	7,725,542	(45,621)
01 March 2022	BNY Mellon	EUR	(406,899)	USD	460,036	(2,716)
01 March 2022	BNY Mellon	EUR	(34,315,718)	USD	38,797,008	(229,106)
01 March 2022	BNY Mellon	EUR	(1,763,076)	USD	1,988,926	(16,161)
01 March 2022	BNY Mellon	NOK	(242,939,800)	USD	27,508,328	(39,611)
01 March 2022	BNY Mellon	NOK	(804,453,214)	USD	91,089,080	(131,166)
01 March 2022	BNY Mellon	NOK	(32,596,808)	USD	3,690,971	(5,315)
01 March 2022	BNY Mellon	NOK	(43,335)	USD	4,827	(87)
01 March 2022	BNY Mellon	NOK	(667,195)	USD	74,244	(1,412)
01 March 2022	BNY Mellon	NOK	(158,439)	USD	17,595	(371)
01 March 2022	BNY Mellon	NOK	(80,401)	USD	8,898	(219)
01 March 2022	BNY Mellon	NOK	(1,330,264)	USD	146,654	(4,190)
01 March 2022	BNY Mellon	NOK	(6,933,968)	USD	762,922	(23,349)
01 March 2022	BNY Mellon	NOK	(27,155,457)	USD	2,987,826	(91,443)
01 March 2022	BNY Mellon	NOK	(1,113,559)	USD	122,521	(3,750)
01 March 2022	BNY Mellon	NOK	(186,173)	USD	20,467	(644)
01 March 2022	BNY Mellon	NOK	(1,717,218)	USD	188,591	(6,131)
01 March 2022	BNY Mellon	NOK	(129,541)	USD	14,219	(470)
01 March 2022	BNY Mellon	NOK	(1,169,012)	USD	128,110	(4,449)
01 March 2022	BNY Mellon	NOK	(517,917)	USD	56,407	(2,322)
01 March 2022	BNY Mellon	SEK	(666,787)	USD	73,757	108
01 March 2022	BNY Mellon	SEK	(27,171,947)	USD	2,999,818	(1,410)
01 March 2022	BNY Mellon	SEK	(853,087)	USD	93,870	(356)
01 March 2022	BNY Mellon	SEK	(166,173)	USD	18,270	(84)
01 March 2022	BNY Mellon	SEK	(52,281)	USD	5,746	(29)
01 March 2022	BNY Mellon	SEK	(386,396)	USD	42,398	(281)
01 March 2022	BNY Mellon	SEK	(1,182,198)	USD	129,629	(948)
01 March 2022	BNY Mellon	SEK	(2,815,405)	USD	308,294	(2,676)
01 March 2022	BNY Mellon	SEK	(488,908)	USD	53,464	(537)
01 March 2022	BNY Mellon	SEK	(981,662)	USD	107,174	(1,254)
01 March 2022	BNY Mellon	USD	(9,774,582)	EUR	8,643,273	55,122
01 March 2022	BNY Mellon	USD	(461,973)	EUR	408,504	2,605
01 March 2022	BNY Mellon	USD	(39,095,509)	EUR	34,570,598	220,471
01 March 2022	BNY Mellon	USD	(248,039)	EUR	218,953	969
01 March 2022	BNY Mellon	USD	(11,637)	EUR	10,272	45
01 March 2022	BNY Mellon	USD	(1,016,404)	EUR	897,215	3,968
01 March 2022	BNY Mellon	USD	(26,876,866)	NOK	244,275,769	822,564
01 March 2022	BNY Mellon	USD	(87,086,906)	NOK	791,506,762	2,665,289
01 March 2022	BNY Mellon	USD	(3,613,125)	NOK	32,838,611	110,580
01 March 2022	BNY Mellon	USD	(2,310,376)	NOK	20,904,026	60,017
01 March 2022	BNY Mellon	USD	(2,945)	NOK	26,593	71
01 March 2022	BNY Mellon	USD	(115,308)	NOK	1,052,187	4,004
01 March 2022	BNY Mellon	USD	(47,528)	NOK	422,668	400
01 March 2022	BNY Mellon	USD	(20,526)	NOK	186,116	578
01 March 2022	BNY Mellon	USD	(98,781)	NOK	878,148	796
01 March 2022	BNY Mellon	USD	(23,269)	NOK	205,537	38
01 March 2022	BNY Mellon	USD	(763,171)	NOK	6,767,011	4,168

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(d) Foreign currency risk (Continued)

Sector Healthcare Value Fund (continued)

Maturity Date	Counterparty	Sale Currency	Amount	Purchase Currency	Amount	Unrealised gain/(loss) USD
01 March 2022	BNY Mellon	USD	(2,397,338)	NOK	21,257,117	13,094
01 March 2022	BNY Mellon	USD	(98,315)	NOK	871,756	537
01 March 2022	BNY Mellon	USD	(3,731,115)	SEK	34,027,301	27,308
01 March 2022	BNY Mellon	USD	(80,976)	SEK	737,543	488
Total unrealised gain on forward foreign currency contracts						**3,805,828**

As at 31 December 2020 the following forward foreign currency contracts were held by the Funds:

Harvest Equity Kernel

Maturity Date	Counterparty	Sale Currency	Amount	Purchase Currency	Amount	Unrealised gain/(loss) USD
19 January 2021	BNY Mellon	AUD	(1,308,757)	NOK	8,631,642	(1,982)
19 January 2021	BNY Mellon	AUD	(7,812,054)	NOK	51,522,839	(11,831)
19 January 2021	BNY Mellon	CAD	(1,316,644)	NOK	9,000,924	17,701
19 January 2021	BNY Mellon	CAD	(7,859,137)	NOK	53,727,107	105,653
19 January 2021	BNY Mellon	CHF	(610,715)	NOK	6,002,231	9,724
19 January 2021	BNY Mellon	CHF	(3,645,397)	NOK	35,827,710	58,042
19 January 2021	BNY Mellon	CNY	(5,114,659)	USD	782,107	(4,204)
19 January 2021	BNY Mellon	CNY	(30,529,737)	USD	4,668,451	(25,088)
19 January 2021	BNY Mellon	EUR	(1,461,715)	NOK	15,476,721	18,292
19 January 2021	BNY Mellon	EUR	(8,725,071)	NOK	92,381,565	109,185
19 January 2021	BNY Mellon	GBP	(75,142)	NOK	879,681	10
19 January 2021	BNY Mellon	GBP	(538,647)	NOK	6,305,884	73
19 January 2021	BNY Mellon	HKD	(2,988,319)	USD	385,505	80
19 January 2021	BNY Mellon	HKD	(18,261,320)	USD	2,355,781	486
19 January 2021	BNY Mellon	INR	(11,160,593)	USD	151,289	(1,277)
19 January 2021	BNY Mellon	INR	(65,751,057)	USD	891,298	(7,521)
19 January 2021	BNY Mellon	JPY	(159,719,419)	NOK	13,427,453	20,895
19 January 2021	BNY Mellon	JPY	(953,375,716)	NOK	80,149,350	124,726
19 January 2021	BNY Mellon	KRW	(200,186,220)	USD	183,408	(696)
19 January 2021	BNY Mellon	KRW	(964,038,950)	USD	883,240	(3,349)
19 January 2021	BNY Mellon	NOK	(531,869)	AUD	81,145	509
19 January 2021	BNY Mellon	NOK	(4,161,752)	AUD	634,939	3,982
19 January 2021	BNY Mellon	NOK	(2,397,022)	CAD	355,541	(862)
19 January 2021	BNY Mellon	NOK	(367,255)	CHF	37,736	(177)
19 January 2021	BNY Mellon	NOK	(2,878,809)	CHF	295,804	(1,391)
19 January 2021	BNY Mellon	NOK	(920,985)	EUR	87,364	(623)
19 January 2021	BNY Mellon	NOK	(7,271,090)	EUR	689,731	(4,914)
19 January 2021	BNY Mellon	NOK	(537,013)	JPY	6,444,370	(287)
19 January 2021	BNY Mellon	NOK	(4,776,213)	JPY	57,316,466	(2,555)
19 January 2021	BNY Mellon	SEK	(1,789,690)	NOK	1,854,230	(1,413)
19 January 2021	BNY Mellon	SEK	(12,244,797)	NOK	12,686,369	(9,665)
19 January 2021	BNY Mellon	TWD	(15,101,523)	USD	542,245	3,564
19 January 2021	BNY Mellon	TWD	(90,141,984)	USD	3,236,696	21,271
19 January 2021	BNY Mellon	USD	(6,148,978)	NOK	53,475,813	96,680
19 January 2021	BNY Mellon	USD	(36,703,652)	NOK	319,200,651	577,094
19 January 2021	BNY Mellon	USD	(711,218)	NOK	6,114,570	2,928
19 January 2021	BNY Mellon	USD	(3,400,705)	NOK	29,236,951	13,998
19 January 2021	BNY Mellon	USD	(139,700)	NOK	1,192,185	(460)
19 January 2021	BNY Mellon	USD	(53,039)	TWD	1,480,318	(235)
19 January 2021	BNY Mellon	USD	(376,063)	TWD	10,495,913	(1,667)
Total unrealised gain on forward foreign currency contracts						**1,104,696**

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(d) Foreign currency risk (Continued)

Sector Healthcare Value Fund

Maturity Date	Counterparty	Sale Currency	Amount	Purchase Currency	Amount	Unrealised gain/(loss) USD
02 January 2021	BNY Mellon	USD	(38,876,557)	EUR	31,686,870	(77,094)
02 January 2021	BNY Mellon	USD	(5,080,830)	EUR	4,141,200	(10,076)
02 January 2021	BNY Mellon	USD	(4,631,004)	EUR	3,774,563	(9,184)
02 January 2021	BNY Mellon	USD	(347,342)	EUR	283,106	(689)
02 January 2021	BNY Mellon	USD	(68,430,327)	GBP	50,530,615	659,172
02 January 2021	BNY Mellon	USD	(25,522,768)	NOK	218,661,236	15,220
02 January 2021	BNY Mellon	USD	(88,311,849)	NOK	756,594,188	52,664
02 January 2021	BNY Mellon	USD	(364,010)	NOK	3,106,289	(1,219)
02 January 2021	BNY Mellon	USD	(52,757)	SEK	431,400	(207)
02 January 2021	BNY Mellon	USD	(2,898,522)	SEK	23,684,689	(13,426)
04 January 2021	BNY Mellon	EUR	(176,886)	USD	215,297	(1,155)
04 January 2021	BNY Mellon	EUR	(313,979)	USD	382,863	(1,347)
04 January 2021	BNY Mellon	EUR	(31,686,870)	USD	38,848,736	74,102
04 January 2021	BNY Mellon	EUR	(4,141,200)	USD	5,077,194	9,685
04 January 2021	BNY Mellon	EUR	(3,774,563)	USD	4,627,690	8,827
04 January 2021	BNY Mellon	EUR	(283,106)	USD	347,094	662
04 January 2021	BNY Mellon	GBP	(50,530,615)	USD	68,413,400	(662,312)
04 January 2021	BNY Mellon	GBP	(50,002)	USD	66,614	(1,739)
04 January 2021	BNY Mellon	NOK	(218,661,236)	USD	25,520,418	(18,267)
04 January 2021	BNY Mellon	NOK	(756,594,188)	USD	88,303,716	(63,207)
04 January 2021	BNY Mellon	NOK	(12,623)	USD	1,473	(1)
04 January 2021	BNY Mellon	NOK	(2,506,757)	USD	292,202	(576)
04 January 2021	BNY Mellon	NOK	(19,523,420)	USD	2,212,749	(67,502)
04 January 2021	BNY Mellon	NOK	(82,551)	USD	9,365	(277)
04 January 2021	BNY Mellon	NOK	(743,287)	USD	83,955	(2,858)
04 January 2021	BNY Mellon	SEK	(23,684,689)	USD	2,897,236	13,080
04 January 2021	BNY Mellon	SEK	(258,241)	USD	31,146	(301)
04 January 2021	BNY Mellon	SEK	(34,928)	USD	4,166	(87)
04 January 2021	BNY Mellon	SEK	(47,771)	USD	5,664	(154)
04 January 2021	BNY Mellon	SEK	(37,211)	USD	4,409	(122)
04 January 2021	BNY Mellon	SEK	(1,348,708)	USD	158,799	(5,437)
04 January 2021	BNY Mellon	USD	(4,950,398)	EUR	4,146,201	123,231
04 January 2021	BNY Mellon	USD	(330,896)	EUR	277,142	8,237
04 January 2021	BNY Mellon	USD	(36,730,874)	EUR	30,763,907	914,347
04 January 2021	BNY Mellon	USD	(4,793,211)	EUR	4,014,549	119,318
04 January 2021	BNY Mellon	USD	(145,309)	EUR	119,227	587
04 January 2021	BNY Mellon	USD	(7,269)	EUR	5,964	29
04 January 2021	BNY Mellon	USD	(1,124,868)	EUR	922,963	4,545
04 January 2021	BNY Mellon	USD	(154,357)	EUR	126,651	624
04 January 2021	BNY Mellon	USD	(5,782,329)	GBP	4,372,265	194,588
04 January 2021	BNY Mellon	USD	(1,767,624)	GBP	1,335,560	58,096
04 January 2021	BNY Mellon	USD	(2,801,177)	GBP	2,100,910	70,782
04 January 2021	BNY Mellon	USD	(47,848,975)	GBP	35,758,466	1,033,103
04 January 2021	BNY Mellon	USD	(6,853,460)	GBP	5,113,416	136,616
04 January 2021	BNY Mellon	USD	(2,566,142)	GBP	1,900,000	31,171
04 January 2021	BNY Mellon	USD	(24,111,290)	NOK	213,375,274	810,017
04 January 2021	BNY Mellon	USD	(83,614,902)	NOK	739,958,435	2,809,038
04 January 2021	BNY Mellon	USD	(58,370)	NOK	515,971	1,893
04 January 2021	BNY Mellon	USD	(61,450)	NOK	542,660	1,930
04 January 2021	BNY Mellon	USD	(65,933)	NOK	576,801	1,435
04 January 2021	BNY Mellon	USD	(187,311)	NOK	1,645,361	4,860
04 January 2021	BNY Mellon	USD	(103,965)	NOK	907,125	1,984
04 January 2021	BNY Mellon	USD	(108,460)	NOK	949,838	2,476
04 January 2021	BNY Mellon	USD	(210,974)	NOK	1,847,084	4,758
04 January 2021	BNY Mellon	USD	(129,494)	NOK	1,141,830	3,867
04 January 2021	BNY Mellon	USD	(257,504)	NOK	2,250,170	5,307
04 January 2021	BNY Mellon	USD	(67,207)	NOK	586,691	1,316
04 January 2021	BNY Mellon	USD	(602,674)	NOK	5,285,962	14,703
04 January 2021	BNY Mellon	USD	(2,446,686)	NOK	21,459,501	59,691
04 January 2021	BNY Mellon	USD	(159,417)	NOK	1,393,204	3,304
04 January 2021	BNY Mellon	USD	(233,122)	NOK	2,025,069	3,397
04 January 2021	BNY Mellon	USD	(74,190)	NOK	638,003	326
04 January 2021	BNY Mellon	USD	(269,499)	NOK	2,337,520	3,513

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(d) Foreign currency risk (Continued)

Sector Healthcare Value Fund (continued)

Maturity Date	Counterparty	Sale Currency	Amount	Purchase Currency	Amount	Unrealised gain/(loss) USD
04 January 2021	BNY Mellon	USD	(78,063)	NOK	674,940	767
04 January 2021	BNY Mellon	USD	(2,802,394)	SEK	23,849,960	101,888
04 January 2021	BNY Mellon	USD	(7,501)	SEK	64,075	301
04 January 2021	BNY Mellon	USD	(8,715)	SEK	74,058	303
04 January 2021	BNY Mellon	USD	(9,749)	SEK	82,863	341
04 January 2021	BNY Mellon	USD	(8,147)	SEK	68,945	249
04 January 2021	BNY Mellon	USD	(3,102)	SEK	26,315	103
04 January 2021	BNY Mellon	USD	(6,368)	SEK	53,893	195
04 January 2021	BNY Mellon	USD	(9,459)	SEK	79,519	224
04 January 2021	BNY Mellon	USD	(11,963)	SEK	100,200	239
04 January 2021	BNY Mellon	USD	(13,199)	SEK	109,000	74
04 January 2021	BNY Mellon	USD	(13,084)	SEK	108,301	104
04 January 2021	BNY Mellon	USD	(75,706)	SEK	631,942	1,248
04 January 2021	BNY Mellon	USD	(18,806)	SEK	155,477	127
04 January 2021	BNY Mellon	USD	(840)	SEK	7,000	12
Total unrealised loss on forward foreign currency contracts						**6,431,440**

(e) Credit risk

Credit risk is the risk that a counterparty will fail to discharge an obligation or commitment that is has entered into with the Funds, resulting in a financial loss to the Funds.

The Funds are exposed to credit risk associated with counterparties with whom it trades or holds assets, and will also be exposed to the risk of settlement default. All transactions in listed securities are settled/paid for upon delivery using approved brokers. The risk of default is considered minimal, as delivery of securities sold is only made once the broker has made payment. Payment is made on a purchase once the securities have been delivered by the broker. The trade will fail if either party fails to meet its obligation.

Management of credit risk
The Investment Manager is complying with the Central Bank UCITS Regulations in terms of investment restrictions and otherwise with the investment policy of the Sub-Funds.

Exposure to credit risk
The Sub-Fund's maximum credit risk exposure at the Balance Sheet date is represented by the respective carrying amounts of the financial assets in the Balance Sheet with the exception of derivatives whose maximum credit risk exposure is notional exposure.

Derivative financial instruments
The Funds may also invest in financial derivative instruments for investment purposes and for efficient portfolio management ("EPM"), including (but not limited to) futures, forwards, options, contracts for difference and warrants.

All cleared derivative positions entered into on behalf of the Funds are cleared via Goldman Sachs as appointed Futures Commission Merchant ("FCMs"). Bilateral (non-cleared) derivatives face BNY as OTC credit counterparty.

Trade counterparty
The Funds mitigate counterparty risk by undertaking transactions with large and well capitalised counterparties. The Funds also seek to trade with more than one counterparty and have reduced the activity with counterparties when there have been questions raised regarding the robustness of counterparties in terms of credit risk.

Although it is the intention of the Investment Managers to follow a general policy of seeking to spread the Funds' capital at risk over a number of investments and counterparties, the Funds may at certain times hold relatively few positions with the result that a loss in any such position either to trading counterparty or settlement default could have a substantial adverse impact on a Fund's capital. The relevant Standard and Poor's ratings are as follows:

	31 December 2021	31 December 2020
The Bank of New York Mellon SA/NV	AA-	AA-
DNB	N/A	AA-
Goldman Sachs	N/A	A+

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(f) Fair value estimation

The Company used the following fair value hierarchy levels in categorising its financial instruments by source of inputs used to determine its fair value:

Level 1: The unadjusted quoted price in an active market for identical assets or liabilities that the entity can access at the measurement date.

Level 2: Inputs other than quoted prices included within Level 1 that are observable (i.e. developed using market data) for the asset or liability, either directly or indirectly.

Level 3: Inputs are unobservable (i.e. for which market data is unavailable) for the asset or liability.

The determination of what constitutes 'observable' requires significant judgement by the Company. The Company considers observable data to be that market data that is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.

Investments classified as Level 3 are those for which a quoted price at year end was unavailable and evidence of a recent transaction at that date could not be ascertained. These investments represent collective investment schemes where the net asset value is calculated by an underlying administrator. The net asset values represent their best evidence of the fair value of these assets at year end, however due to the lack of quoted price and evidence of a recent transaction, a Level 3 classification is considered appropriate.

The level in the fair value hierarchy within which the fair value measurement is categorised is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety. For this purpose, the significance of an input is assessed against the fair value measurement in its entirety. If a fair value measurement uses inputs that are unobservable, that measurement is a Level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgement, considering factors specific to the asset or liability.

There were no significant transfers between levels during the financial year ended 31 December 2021 or 31 December 2020. Transfers between levels of the fair value hierarchy, for the purpose of disclosure in financial statements, are deemed to have occurred at the end of the reporting period.

The fair values of investments valued under Levels 1 to 3 for Sector Healthcare Value Fund as at 31 December 2021 are as follows.

Sector Healthcare Value Fund	**Level 1 USD**	**Level 2 USD**	**Level 3 USD**	**Total USD**
Financial assets at fair value through profit or loss				
Equity securities	478,684,329	–	–	478,684,329
Derivative instruments	–	4,431,396	–	4,431,396
Financial liabilities at fair value through profit or loss				
Derivative instruments	–	(625,568)	–	(625,568)
Total	**478,684,329**	**3,805,828**	**–**	**482,490,157**

The categories of investments above comprise:
- Equity securities (which includes equities and money market funds).
- Derivative instruments (forward foreign currency contracts).

The fair values of investments valued under Levels 1 to 3 as at 31 December 2020 are as follows:

Harvest Equity Kernel	**Level 1 USD**	**Level 2 USD**	**Level 3 USD**	**Total USD**
Financial assets at fair value through profit or loss				
Equity securities	108,106,219	–	–	108,106,219
Derivative instruments	–	1,449,869	–	1,449,869
Financial liabilities at fair value through profit or loss				
Derivative instruments	–	(301,921)	–	(301,921)
Total	**108,106,219**	**1,147,948**	**–**	**109,254,167**

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(f) Fair value estimation (Continued)

Sector Healthcare Value Fund	**Level 1 USD**	**Level 2 USD**	**Level 3 USD**	**Total USD**
Financial assets at fair value through profit or loss				
Equity securities	347,072,780	–	–	347,072,780
Derivative instruments	–	7,368,676	–	7,368,676
Financial liabilities at fair value through profit or loss				
Derivative instruments	–	(937,236)	–	(937,236)
Total	**361,072,780**	**6,431,440**	**–**	**367,504,220**

The categories of investments above comprise:

- Equity securities (which includes equities, real estate investment trusts and rights).
- Derivative instruments (which includes forward foreign currency contracts, contracts-for-difference, futures and options).

8. Share Capital

The authorised share capital of the Company is 1,000,000,000,000 Shares of no par value initially designated as unclassified shares. The issued share capital of the Company is €2 represented by 2 shares (the "Subscriber Shares") issued for the purposes of the incorporation of the Company at an issue price of €1 per Share which are fully paid up and which are beneficially owned by Sector Asset Management AS and Prieren AS.

Harvest Equity Kernel may have issued Class A EUR Shares, Class A USD Shares, Class A NOK Shares Hedged, Shares, Class A NOK Unhedged Shares and Class A SEK Shares (the "Class A Shares"), Class B Shares, which are comprised of Class B EUR Shares, Class B USD Shares, Class B NOK Hedged Shares, Class B NOK Unhedged Shares and Class B SEK (the "Class B Shares"), Class C EUR Shares, Class C USD Shares, Class C NOK Shares and Class C SEK Shares (the "Class C Shares"), Class P USD Shares, Class P NOK Hedged Shares and Class P NOK Unhedged Shares ("the Class P Shares") and Class O NOK Shares.

Sector Healthcare Value Fund may issue Class A EUR Shares, Class A USD Shares, Class A NOK Shares and Class A SEK Shares, (the "Class A Shares"), B EUR Shares, Class B USD Shares, Class B NOK Shares and Class B SEK (the "Class B Shares"), Class E EUR Shares, Class E SEK Shares, Class E NOK Shares and Class E USD Shares (the "Class E Shares"), Class X EUR Shares and Class X USD Shares (the "Class X Shares") and Class Y EUR Shares, Class Y GBP Shares and Class Y USD Shares (the "Class Y Shares").

On a show of hands every holder who is present in person or by proxy shall have one vote and the holders of Subscriber Shares present or in person or by proxy shall have one vote.

The rights attached to any class may be varied or abrogated with the consent in writing of the holders of three-fourths in number of the issued Shares of that class, or with the sanction of a special resolution passed at a separate general meeting of the holders of the Shares of the class, and may be so varied or abrogated either whilst the Company is a going concern or during or in contemplation of a winding-up. The quorum at any such separate general meeting, other than an adjourned meeting, shall be two persons holding or representing by proxy at least one third of the issued Shares of the class in question and the quorum at an adjourned meeting shall be one person holding Shares of the class in question or his proxy.

NOTES TO THE FINANCIAL STATEMENTS (Continued)

8. Share Capital (Continued)

The following are the share class transactions for the financial year ended 31 December 2021 were as follows:

	Harvest Equity Kernel	Sector Healthcare Value Fund
Class A EUR		
Shares in issue at beginning of year	–	11,959
Number of shares issued	–	13,541
Number of shares redeemed	–	(5,771)
Number in issue at end of year	–	19,729
Class A NOK		
Shares in issue at beginning of year	104,603	77,368
Number of shares issued	1,888	4,906
Number of shares redeemed	(106,491)	(3,984)
Number in issue at end of year	–	78,290
Class A USD		
Shares in issue at beginning of year	164	65,122
Number of shares issued	–	16,672
Number of shares redeemed	(164)	(25,963)
Number in issue at end of year	–	55,831
Class B EUR		
Shares in issue at beginning of year	–	2,107
Number of shares issued	–	2,090
Number of shares redeemed	–	(1,357)
Number in issue at end of year	–	2,840
Class B NOK		
Shares in issue at beginning of year	–	490,694
Number of shares issued	–	102,941
Number of shares redeemed	–	(108,364)
Number in issue at end of year	–	485,271
Class B SEK		
Shares in issue at beginning of year	–	16,371
Number of shares issued	–	9,888
Number of shares redeemed	–	(9,404)
Number in issue at end of year	–	16,855
Class B USD		
Shares in issue at beginning of year	–	187,407
Number of shares issued	–	238,381
Number of shares redeemed	–	(142,088)
Number in issue at end of year	–	283,700
Class P NOK		
Shares in issue at beginning of year	640,165	–
Number of shares issued	–	–
Number of shares redeemed	(640,165)	–
Number in issue at end of year	–	–

NOTES TO THE FINANCIAL STATEMENTS (Continued)

8. Share Capital (Continued)

	Harvest Equity Kernel	Sector Healthcare Value Fund
Class P NOK Unhedged		
Shares in issue at beginning of year	227,923	–
Number of shares issued	2,505	–
Number of shares redeemed	(230,428)	–
Number in issue at end of year	–	–
Class P USD		
Shares in issue at beginning of year	327	–
Number of shares issued	–	–
Number of shares redeemed	(327)	–
Number in issue at end of year	–	–
Class X EUR		
Shares in issue at beginning of year	–	309,159
Number of shares issued	–	–
Number of shares redeemed	–	–
Number in issue at end of year	–	309,159
Class X USD		
Shares in issue at beginning of year	–	176,532
Number of shares issued	–	99,914
Number of shares redeemed	–	(8,314)
Number in issue at end of year	–	268,132
Class E NOK		
Shares in issue at beginning of year	–	–
Number of shares issued	–	312,914
Number of shares redeemed	–	(6,189)
Number in issue at end of year	–	306,725
Class E USD		
Shares in issue at beginning of year	–	–
Number of shares issued	–	73,494
Number of shares redeemed	–	–
Number in issue at end of year	–	73,494
Class Y EUR		
Shares in issue at beginning of year	–	39,316
Number of shares issued	–	1,509
Number of shares redeemed	–	(2,771)
Number in issue at end of year	–	38,054
Class Y GBP		
Shares in issue at beginning of year	–	479,279
Number of shares issued	–	181,881
Number of shares redeemed	–	(4,038)
Number in issue at end of year	–	657,122
Class Y USD		
Shares in issue at beginning of year	–	419,660
Number of shares issued	–	149,300
Number of shares redeemed	–	(62,158)
Number in issue at end of year	–	506,802

NOTES TO THE FINANCIAL STATEMENTS (Continued)

8. Share Capital (Continued)
The following are the share class transactions for the financial year ended 31 December 2020 were as follows:

	Harvest Equity Kernel	Sector Healthcare Value Fund
Class A EUR		
Shares in issue at beginning of year	–	17,800
Number of shares issued	–	3,271
Number of shares redeemed	–	(9,112)
Number in issue at end of year	–	11,959
Class A NOK		
Shares in issue at beginning of year	96,170	39,187
Number of shares issued	43,673	39,633
Number of shares redeemed	(35,240)	(1,452)
Number in issue at end of year	104,603	77,368
Class A USD		
Shares in issue at beginning of year	121	66,547
Number of shares issued	165	17,755
Number of shares redeemed	(122)	(19,180)
Number in issue at end of year	164	65,122
Class B EUR		
Shares in issue at beginning of year	–	1,757
Number of shares issued	–	750
Number of shares redeemed	–	(400)
Number in issue at end of year	–	2,107
Class B NOK		
Shares in issue at beginning of year	–	402,316
Number of shares issued	–	263,861
Number of shares redeemed	–	(175,483)
Number in issue at end of year	–	490,694
Class B SEK		
Shares in issue at beginning of year	–	12,067
Number of shares issued	–	10,073
Number of shares redeemed	–	(5,769)
Number in issue at end of year	–	16,371
Class B USD		
Shares in issue at beginning of year	–	62,929
Number of shares issued	–	171,339
Number of shares redeemed	–	(46,861)
Number in issue at end of year	–	187,407
Class L NOK		
Shares in issue at beginning of year	–	24,461
Number of shares issued	–	–
Number of shares redeemed	–	(24,461)
Number in issue at end of year	–	–
Class P NOK		
Shares in issue at beginning of year	682,819	–
Number of shares issued	70,202	–
Number of shares redeemed	(112,856)	–
Number in issue at end of year	640,165	–

NOTES TO THE FINANCIAL STATEMENTS (Continued)

8. Share Capital (Continued)

	Harvest Equity Kernel	Sector Healthcare Value Fund
Class P NOK Unhedged		
Shares in issue at beginning of year	296,293	–
Number of shares issued	233,207	–
Number of shares redeemed	(301,577)	–
Number in issue at end of year	227,923	–
Class P USD		
Shares in issue at beginning of year	405	–
Number of shares issued	–	–
Number of shares redeemed	(78)	–
Number in issue at end of year	327	–
Class X EUR		
Shares in issue at beginning of year	–	–
Number of shares issued	–	309,159
Number of shares redeemed	–	–
Number in issue at end of year	–	309,159
Class X USD		
Shares in issue at beginning of year	–	225,724
Number of shares issued	–	41,561
Number of shares redeemed	–	(90,753)
Number in issue at end of year	–	176,532
Class Y EUR		
Shares in issue at beginning of year	–	–
Number of shares issued	–	39,316
Number of shares redeemed	–	–
Number in issue at end of year	–	39,316
Class Y GBP		
Shares in issue at beginning of year	–	–
Number of shares issued	–	481,011
Number of shares redeemed	–	(1,732)
Number in issue at end of year	–	479,279
Class Y USD		
Shares in issue at beginning of year	–	–
Number of shares issued	–	420,013
Number of shares redeemed	–	(353)
Number in issue at end of year	–	419,660

NOTES TO THE FINANCIAL STATEMENTS (Continued)

9. Investment Management Fees

From 5 February 2021, the Company has appointed Sector Funds Services AS from Harvest Funds AS *(from 2 January 2020 up to their resignation on 5 February 2021)* and Sector Gamma AS the Investment Managers.

Harvest Equity Kernel and Sector Healthcare Value Fund pays the Investment Manager a management fee per annum of the Net Asset Value of each of the following classes:

Harvest Equity Kernel		Sector Healthcare Value Fund	
Class	**Management Fee**	**Class**	**Management Fee**
Class A Shares	Up to 1.50%	Class A Shares	Up to 1.0%
Class B Shares	Up to 0.75%	Class B Shares	Up to 2.0%
Class C Shares	Up to 0.50%	Class E Shares	Up to 1.0%
Class P Shares	Up to 0.50%	Class X Shares	Up to 0.50%
Class O Shares	Up to 3.00%	Class Y Shares	Up to 0.40%

The Investment Manager does not charge a fee in respect of the Class L NOK Shares.

The total management fees accrued for the financial year ended 31 December 2021 were USD4,570,216 (31 December 2020: USD3,474,382) and the net amount outstanding at 31 December 2021 was USD391,047 (31 December 2020: USD490,075).

10. Incentive Fees/Performance Fees

The Investment Manager is also entitled to receive an incentive fee/performance fee ("Incentive Fee" / "Performance Fee"), as calculated for each Fund as disclosed below. The Incentive Fee/Performance Fee will be verified by the Depositary.

Harvest Equity Kernel

The Fund, in respect of the Class C Shares and Class O Shares paid the Investment Manager an incentive fee (the "Incentive Fee") equal to 10% of the amount by which the Net Asset Value (before the deduction of any performance fee) of the relevant Class exceeds the MSCI ACWI Index ("Index") adjusted Prior High Net Asset Value ("Index adjusted Prior High Net Asset Value") (as defined below). No Incentive Fee is charged in respect of the Class A Shares, Class B Shares, Class P Shares and Class L NOK Shares.

The Incentive Fee is calculated on a share-by-share basis so that each share is charged a fee which equates precisely with that share's performance over each Calculation Year (as defined below). This method of calculation ensures that (i) any Incentive Fee paid to the Investment Manager is charged only to those shares which have outperformed their respective Prior High Net Asset Value over the course of a Calculation Year, (ii) all holders of shares have the same amount of capital per share at risk in the Fund, and (iii) all shares in a particular class have the same net asset value per share.

The Incentive Fee shall only be payable on the amount by which each share outperforms the previous high watermark or Index adjusted Prior High Net Asset Value for the relevant share. For each Calculation Year, an Incentive Fee will only be payable by a particular share if the net asset value of that share at the end of a Calculation Year is greater than the prevailing Prior High Net Asset Value for that share.

The "Prior High Net Asset Value" of each share is the highest net asset value per share on which Incentive Fee was paid in respect of any previous Calculation Year (or, if no Incentive Fee has yet been paid with respect to any such Calculation Year, the Initial Issue Price of the relevant share). The "Index adjusted Prior High Net Asset Value" of each share is the Prior High Net Asset Value adjusted by the performance of the Index for the relevant Calculation Year. The calculation year for the Incentive Fee shall be a calendar year, closing on the 31 December each year (or if the 31 December is not a Business Day, on the last Business Day of the year) (the "Calculation Year"). The Incentive Fee will accrue as at each valuation point and shall be payable annually in arrears (on or after the first business day of the following year).

Sector Healthcare Value Fund

The Fund, in respect of the Class A Shares, pays the Investment Manager a fee equal to 20% of the amount by which the net asset value (before the deduction of any performance fee) of the relevant share exceeds the MSCI Daily TR World Net Healthcare USD (the "Index"). In respect of Class E Shares, a fee equal to 20% of the amount by which the net asset value (before the deduction of any performance fee) of the relevant share exceeds the Index adjusted Prior High Net Asset Value (the "Incentive Fee"). In respect of Class X Shares and Class Y Shares, a fee equal to 15% of the amount by which the net asset value (before the deduction of any performance fee) of the relevant share exceeds the Index Net Asset Value (the "Incentive Fee").

NOTES TO THE FINANCIAL STATEMENTS (Continued)

10. Incentive Fees/Performance Fees (Continued)

The relevant share's subscription price or the initial issue price (where shares are issued during the initial offer year) is taken as the starting price for the purposes of determining the Incentive Fee. The Incentive Fee is accrued on a daily basis and reflected in the net asset value per share at each valuation point. The accrued Incentive Fee will only be paid to the Investment Manager once a shareholder redeems its investment in the Fund or when the Fund closes down where the performance of the relevant shares has exceeded the performance of the Index. The Incentive Fee may be payable even if the absolute return on the shareholder's investment is zero or negative. For example, if during the year of a shareholder's investment in the Fund, the net asset value per share on redemption is less than or equal to the net asset value per share that that shareholder paid on its initial subscription into the Fund, the Incentive Fee may still be payable if the net asset value per share on redemption exceeds the Index Net Asset Value per share, i.e. the Fund has outperformed the Index for the year of the shareholder's investment. No Incentive Fee will be charged in respect of the Class B Shares.

During the year ended 31 December 2021, there was a reversal of accrued Performance Fees which resulted in a net credit of USD102,056 (31 December 2020: USD239,439) to the profit and loss account with USD199,820 (31 December 2020: USD317,753) payable at the year end.

Equalisation Credit

The equalisation credit policy is applied to the calculation of the Incentive Fee payable for certain classes in each Fund (see the Fund’s relevant Supplement for further details). The Incentive Fee is calculated on a share-by-share basis so that each relevant share is charged an Incentive Fee that equates precisely with that relevant share’s performance. This method of calculation ensures that (i) the Incentive Fee is charged only to those relevant shares that have appreciated in value relative to the Index, (ii) all relevant shareholders have the same amount per relevant share of the relevant class at risk in the Fund, and (iii) all shares of the same class have the same net asset value per share. If a shareholder subscribes for relevant shares at a time when the net asset value per relevant share is other than the Index Net Asset Value, certain adjustments will be made to reduce inequities that could otherwise result to the subscriber or beneficiary of the Incentive Fee. For the financial year ended 31 December 2021 an equalisation credit of USD103,043 (31 December 2020: USD1,225,673) was applied by the Company.

11. Administration Fees and Depositary/Custodian Fees

The Company has appointed BNY Mellon Fund Services (Ireland) Designated Activity Company (“BNY Mellon”) to act as Administrator, registrar and transfer agent and The Bank of New York Mellon SA/NV, Dublin Branch to act as Depositary (the “Depositary”). BNY Mellon is entitled to receive out of the assets of the Funds an annual administration fee, accrued and calculated on each dealing day and payable monthly in arrears of up to 0.105% of the aggregated Net Assets. BNY Mellon is also entitled to a shareholding services fee of USD1,875 per share class per month together with agreed upon transaction charges. The Administrator is also entitled to a financial reporting fee of up to USD5,000 per set of financial statements and other out of pocket expenses out of the assets of the Funds (plus VAT thereon if any).

The Administration fee accrued for the financial year ended 31 December 2021 was USD491,171 (31 December 2020: USD520,615) and the amount outstanding at 31 December 2021 was USD91,600 (31 December 2020: USD130,152).

The Depositary is entitled to an asset based fee of up to 0.02% per annum payable monthly together with sub-custodians’ fees (which will be charged at normal commercial rates) as well as agreed upon transaction charges (which will be at normal commercial rates) and other out of pocket expenses (plus VAT thereon if any).

The Depositary fee accrued for the financial year ended 31 December 2021 was USD179,016 (31 December 2020: USD181,742) and the amount outstanding at 31 December 2021 was USD13,399 (31 December 2020: USD24,901).

12. Directors’ Fees and Expenses

The Directors shall be entitled to a fee in remuneration for their services at a rate to be determined from time to time by the Directors, but so that the aggregate amount of each Director’s remuneration in any one year shall not exceed €15,000 (31 December 2020: €15,000) or such higher amount as may be approved by resolution of the Directors and notified to shareholders. The Directors may also be paid all travelling, hotel and other expenses, properly incurred by them, in attending and returning from meetings of the Directors or general meetings of the Company or in connection with the business of the Company. The Directors may in addition to such remuneration as aforesaid grant special remuneration to any Director who, being called upon, shall perform any special or extra services to or at the request of the Company and such remuneration will be at normal commercial rates. The Directors’ fees and expenses accrued for the financial year ended 31 December 2021 was USD38,188 (31 December 2020: USD34,533) and the amount outstanding at 31 December 2021 was USD11,759 (31 December 2020: USD14,642).

NOTES TO THE FINANCIAL STATEMENTS (Continued)

13. Auditors' Fees

Fees and expenses paid to the statutory auditors, Deloitte Ireland LLP, in respect of the financial year, entirely relate to the audit of the financial statements of the Company.

Audit fees charged for the financial year ended 31 December 2021 were EUR17,000 ex VAT (31 December 2020: EUR18,000). Tax compliance fees charged for the financial year ended 31 December 2021 were EUR8,600 ex VAT (31 December 2020: EUR7,600).

14. Efficient Portfolio Management

The Company may enter into a variety of derivative instruments including, but not limited to, forward foreign exchange contracts, futures, options, swaps, contracts-for-difference, stock lending and repurchase agreements for the purposes of efficient portfolio management only, subject to the conditions and limits set out in the Central Bank (Supervision and Enforcement) Act 2013 (Section 48 (1)) (Undertakings for Collective Investment in Transferable Securities) Regulations 2019 (the "Central Bank UCITS Regulations") and within any further limits laid down by the Central Bank of Ireland from time to time. In particular, the Funds may engage in forward foreign exchange contracts to provide protection against exchange rate risks, including cross-currency hedging, and in order to hedge foreign currency exposure of the underlying assets of the Funds into the base currency of the Funds or into a currency institutionally linked to the base currency. It is intended that the use of such forwards may reduce the currency risk in respect of the Funds and will better enable the Funds to manage its assets and liabilities. Futures contracts may be used to hedge or gain exposure to an increase in the value of an asset, market, currency, or deposit. Options may be used to hedge or achieve exposure to a particular market instead of using a physical security. Swaps may be used to achieve profit as well as to hedge existing long positions. Contracts-for-difference ("CFDs") are bilateral agreements to exchange the difference between opening and closing contracts, which represent the performance of an underlying share.

At the discretion of the Directors, the Funds may use financial derivative instruments as a primary investment policy and details of the investment policy will be set out in the applicable Supplement in accordance with the requirements of the Central Bank of Ireland.

For the year ended 31 December 2021 and 31 December 2020, the Company has utilised forward foreign currency contracts. As at 31 December 2021, all derivatives are OTC derivatives. All open derivative positions are disclosed in the schedule of investments except for forward currency contracts which are disclosed in note 7 (d) above.

15. Directors' Interests, Connected Persons and Related Party Transactions

Fees payable to the relevant Investment Manager are disclosed in notes 9 and 10.

Depositary and Administrator
Although not deemed to be related parties under FRS 102 as they do not exercise "significant influence" over the activities of the Company, the Regulations also deem a "Depositary" and its "associated or group companies" to be "connected persons" to the Company. As such, The Bank of New York Mellon SA/NV, Dublin Branch, the Depositary, and BNY Mellon Fund Services (Ireland) Designated Activity Company, the Administrator, are connected persons to the Company.

The Board of Directors is satisfied that there are arrangements (evidenced by written procedures) in place, to ensure that any transaction carried out with the Company by a promoter, manager, depositary/custodian, investment manager and/or associated or group companies of these ("connected persons") are carried out as if negotiated at arm's length and that all such transactions are carried out in the best interests of the shareholders. The Board of Directors are satisfied that transactions with connected persons entered into during the year complied with the obligations set out in the Regulations.

NOTES TO THE FINANCIAL STATEMENTS (Continued)

15. Directors' Interests, Connected Persons and Related Party Transactions (Continued)

31 December 2021

Key personnel	Role/Team	Fund/Class	Number of Shares held
Tellaviva/Lars Tell	Director	Sector Healthcare Value Fund, Class A NOK	326
ETHO AS/ Trond Horneland	Investment Manager	Sector Healthcare Value Fund, Class A NOK	22,040
Sector Gamma AS	Investment Manager	Sector Healthcare Value Fund, Class B SEK	118

31 December 2020

Key personnel	Role/Team	Fund/Class	Number of Shares held
Tellaviva/Lars Tell	Director	Sector Healthcare Value Fund, Class A NOK	250
Meditek Capital AS/ Trond Tviberg	Investment Manager, Sector Gamma AS	Sector Healthcare Value Fund, Class A NOK	8,976
ETHO AS/ Trond Horneland	Investment Manager	Sector Healthcare Value Fund, Class A NOK	22,040
Sector Gamma AS	Investment Manager	Sector Healthcare Value Fund, Class B SEK	118
Sector Omega DTR AS	Company wholly owned by Harvest Funds AS	Harvest Equity Kernel, Class P USD	134

As at 31 December 2021 and 31 December 2020, Sector Asset Management AS held 3 Class A EUR Shares, 2 Class A NOK Shares and 3 Class A USD Shares in Sector Healthcare Value Fund.

16. Contingent Liabilities

The Company is established as a segregated portfolio company. As a matter of Irish law, the assets of one Fund will not be available to satisfy the liabilities of another. However, the Company is a single legal entity which may operate or have assets held on its behalf or be subject to claims in other jurisdictions which may not necessarily recognise such segregation. There is no guarantee that the courts of any jurisdiction outside Ireland will respect the limitations on liability associated with segregated portfolio companies nor is there any guarantee that the creditors of one Fund will not seek to enforce such Fund's obligations against another Fund.

As at 31 December 2021 and 31 December 2020 there were no known contingent liabilities.

17. Soft Commission

There were no soft commissions for the financial year ended 31 December 2021 and 31 December 2020.

18. IMR Regulations

In response to the CBI publishing the Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) Investor Money Regulations 2015 for Fund Service Providers (the "Investor Money Regulations" or "IMR") issued in March 2015, subscription and redemption monies will (effective from 1 July 2016), be channeled through a sub-fund cash collection account in the name of the sub-fund. Pending issue of the shares and/or payment of subscription proceeds to an account in the name of the sub-fund(s), and pending payment of redemption proceeds or distributions, the relevant investor will be an unsecured creditor of the sub-fund in respect of amounts paid by or due to it. As at 31 December 2021 and at 31 December 2020 the Fund has received subscriptions in advance and these amounts are reflected on the Balance Sheet.

19. Comparative Year

The prior year comparatives are for the financial year 1 January 2020 to 31 December 2020.

NOTES TO THE FINANCIAL STATEMENTS (Continued)

20. Three Year Historical Net Asset Value

The following tables outline the number of shares outstanding and the Net Asset Value per share for each share class for the last three reporting periods.

31 December 2021

	Harvest Equity Kernel USD	Sector Healthcare Value Fund USD
Total Net Asset Value	–	480,884,750
Shares outstanding		
Class A EUR	–	19,729
Class A NOK	–	78,290
Class A USD	–	55,831
Class B EUR	–	2,840
Class B NOK	–	485,271
Class B SEK	–	16,855
Class B USD	–	283,700
Class X EUR	–	309,159
Class X USD	–	268,132
Class E NOK	–	306,725
Class E USD	–	73,494
Class Y EUR	–	38,054
Class Y GBP	–	657,122
Class Y USD	–	506,802
Net Asset Value per Share		
Class A EUR	–	349.87
Class A NOK	–	3,132.26
Class A USD	–	527.12
Class B EUR	–	144.51
Class B NOK	–	1,675.18
Class B SEK	–	1,586.41
Class B USD	–	169.79
Class X EUR	–	111.98
Class X USD	–	180.40
Class E NOK	–	107.21
Class E USD	–	102.57
Class Y EUR	–	124.71
Class Y GBP	–	122.32
Class Y USD	–	115.92

31 December 2020

	Harvest Equity Kernel USD	Sector Healthcare Value Fund USD
Total Net Asset Value	124,692,469	367,309,862
Shares outstanding		
Class A EUR	–	11,959
Class A NOK	104,603	77,368
Class A USD	164	65,122
Class B EUR	–	2,107
Class B NOK	–	490,694
Class B SEK	–	16,371
Class B USD	–	187,407
Class P NOK	640,165	–
Class P NOK Unhedged	227,923	–
Class P USD	327	–
Class X EUR	–	309,159
Class X USD	–	176,532
Class Y EUR	–	39,316

NOTES TO THE FINANCIAL STATEMENTS (Continued)

20. Three Year Historical Net Asset Value (Continued)

31 December 2020

	Harvest Equity Kernel USD	Sector Healthcare Value Fund USD
Class Y GBP	–	479,279
Class Y USD	–	419,660
Net Asset Value per Share		
Class A EUR	–	315.87
Class A NOK	1,096.67	2,823.79
Class A USD	143.30	474.05
Class B EUR	–	133.94
Class B NOK	–	1,544.85
Class B SEK	–	1,468.78
Class B USD	–	155.66
Class P NOK	1,032.92	–
Class P NOK Unhedged	1,276.70	–
Class P USD	166.26	–
Class X EUR	–	102.27
Class X USD	–	162.20
Class Y EUR	–	105.19
Class Y GBP	–	105.40
Class Y USD	–	104.59

31 December 2019

	Harvest Equity Kernel USD	Sector Healthcare Value Fund USD
Total Net Asset Value	127,320,414	167,225,950
Shares outstanding		
Class A EUR	–	17,800
Class A NOK	96,170	39,187
Class A USD	121	66,547
Class B EUR	–	1,757
Class B NOK	–	402,316
Class B SEK	–	12,067
Class B USD	–	62,929
Class L NOK	–	24,461
Class P NOK	682,819	–
Class P NOK Unhedged	296,293	–
Class P USD	405	–
Class X USD	–	225,724
Net Asset Value per Share		
Class A EUR	–	293.55
Class A NOK	1,050.90	2,639.05
Class A USD	130.68	433.91
Class B EUR	–	126.49
Class B NOK	–	1,473.45
Class B SEK	–	1,394.22
Class B USD	–	144.37
Class L NOK	–	3,172.37
Class P NOK	975.46	–
Class P NOK Unhedged	1,184.64	–
Class P USD	150.31	–
Class X USD	–	147.50

NOTES TO THE FINANCIAL STATEMENTS (Continued)

21. Significant Events during the financial year

Upon recommendation from the Investment Manager, Harvest Funds AS, the Directors resolved to terminate Harvest Equity Kernel, with effect from 15 January 2021. The Directors will seek revocation of the approval of the Fund from the Central Bank of Ireland.

On 5 February 2021, Harvest Funds AS resigned as Investment Manager and with immediate effect Sector Funds Services AS was appointed as the Investment Manager.

A revised supplement for Sector Healthcare Value Fund was noted by the Central Bank of Ireland on 3 March 2021.

A revised supplement for Sector Healthcare Value Fund was noted by the Central Bank of Ireland on 18 May 2021.

Effective 21 May 2021, Sector Sigma Nordic Fund's authorisation was revoked by the Central Bank of Ireland.

A revised supplement for Sector Healthcare Value Fund was noted by the Central Bank of Ireland on 31 December 2021.

There were no other significant events during the financial year.

Market disturbances

The global public health crisis which arose from the outbreak of the novel coronavirus disease (known as COVID-19) has caused considerable volatility and disruption in financial markets since early March 2020. It is unknown what the impact will be on the global economy but the uncertainty and instability from COVID-19 for a prolonged period could have an adverse impact on the Company's or relevant Fund’s business, opportunities, operations, financial condition and cash flows and there can be no assurance that the risks associated with COVID-19 will not alter significantly the attractiveness of an investment in the Company or a Fund as a result of the potential for capital losses and general uncertainty.

There were no other significant events during the year.

22. Significant Events after the Balance Sheet Date

We have assessed the possible impact on our business, to the extent possible, related to developments in Ukraine after 24 February 2022, as well as to sanctions imposed on Russia. The Company has no operations, investors, or suppliers in these countries. Trading counterparties are monitored from a risk perspective. The Company has no direct exposure to Ukraine or Russia.

There were no other significant events after the balance sheet date.

23. Approval of Financial Statements

The financial statements were authorised for issue by the Directors on 22 March 2022.

SIGNIFICANT PORTFOLIO MOVEMENTS (Unaudited)

In accordance with the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48 (1) (Undertakings for Collective Investment in Transferable Securities) Regulations, 2019, a statement of the largest changes in the composition of the Schedule of Investments during the year is provided to ensure that the shareholders can identify changes in the investments held by the Fund. These statements present the aggregate purchases and sales of an investment, exceeding 1% of the total value of purchases and sales for the year. At a minimum the largest 20 purchases and sales are listed. If the Fund enters into less than 20 purchases or sales during the year, then all transactions are presented.

Harvest Equity Kernel

LARGEST PURCHASES	COST $
GlaxoSmithKline Plc	15,720

LARGEST SALES	PROCEEDS $
Goldman Sachs US$ Treasury Liquid Reserves Fund	8,000,000
Azbil Corp.	3,125,276
Fortescue Metals Group Ltd.	2,375,444
United Microelectronics Corp.	2,349,984
Roche Holding AG	2,077,957
Thermo Fisher Scientific, Inc.	2,006,206
Samsung Electronics Co., Ltd.	1,992,173
Tokyo Electron Ltd.	1,883,927
Dollar General Corp.	1,755,837
Sony Group Corp.	1,716,556
Newmont Corp.	1,670,155
Murata Manufacturing Co., Ltd.	1,642,549
Taiwan Semiconductor Manufacturing Co., Ltd.	1,617,834
Zebra Technologies Corp.	1,611,253
Barry Callebaut AG	1,609,781
B2Gold Corp.	1,599,767
Peugeot S.A.	1,595,490
Wesfarmers Ltd.	1,577,790
AutoNation,Inc.	1,570,797
STMicroelectronics NV	1,520,119

SIGNIFICANT PORTFOLIO MOVEMENTS (Unaudited) (Continued)

Sector Healthcare Value Fund

LARGEST PURCHASES	COST $
Goldman Sachs US$ Treasury Liquid Reserves Fund	18,701,882
Pfizer, Inc.	17,559,390
GlaxoSmithKline Plc	13,332,955
Bristol-Myers Squibb Co.	12,660,607
Merck & Co., Inc.	10,912,395
Baxter International, Inc.	9,752,644
UCB S.A.	9,137,107
Organon & Co.	8,711,605
Biogen, Inc.	8,672,674
Gilead Sciences, Inc.	8,587,945
Henry Schein, Inc.	8,382,710
BioMarin Pharmaceutical, Inc.	8,175,369
Johnson & Johnson	7,328,878
Novartis AG	6,840,501
Eisai Co. Ltd.	6,132,629
Ionis Pharmaceuticals, Inc.	5,474,016
Centene Corp.	5,071,316
QIAGEN NV	4,685,565
Hologic, Inc.	4,570,185
H Lundbeck A/S	4,381,261

LARGEST SALES	PROCEEDS $
Goldman Sachs US$ Treasury Liquid Reserves Fund	12,701,882
Alexion Pharmaceuticals, Inc.	11,359,294
Abbott Laboratories	10,931,476
Gilead Sciences, Inc.	10,303,613
Merck KGaA	8,404,055
Johnson & Johnson	7,997,923
Merck & Co., Inc.	7,783,429
Novartis AG	7,030,442
HCA Holdings, Inc.	6,815,110
LivaNova Plc	6,503,916
Sanofi	6,342,574
BioNTech SE	5,568,510
Astellas Pharma, Inc.	5,510,191
GlaxoSmithKline Plc	5,341,796
Bristol-Myers Squibb Co.	4,831,760
BioMarin Pharmaceutical, Inc.	4,746,521
Boston Scientific Corp.	4,556,579
Biogen, Inc.	4,412,592
Becton Dickinson & Co.	4,409,782
Ionis Pharmaceuticals, Inc.	4,382,065

REMUNERATION INFORMATION (Unaudited)

Regulation 89(3A) of the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 (S.I. No. 352 of 2011), as amended (the "UCITS Regulations") (as introduced pursuant to the European Union (Undertakings for Collective Investment in Transferable Securities) (Amendment) Regulations 2016 (the "UCITS V Regulations") on 21 March 2016) requires that the annual report of the Company contains certain disclosures on remuneration paid by the Company to its staff during the financial year and details of any material changes to the Company's remuneration policy made during the period.

In this regard, the following points are to be noted:

- The Company has prepared a remuneration policy outlining how it adheres to the remuneration requirements set out in the UCITS Regulations and ESMA's Guidelines on sound remuneration policies under the UCITS Directive (ESMA/2016/575) (the "Guidelines"). This policy was adopted with effect from 1 January 2018.
- No annual reviews have as yet been undertaken and no material changes have been made to the remuneration policy since 1 January 2020.

The Company has no employees or staff that it employs and pays directly. The Company has a Board of Directors, one of whom is an employee of the Sector group and receives no remuneration from the Company. The remaining two directors, each of whom is independent, receive a fixed fee only for the year ended 31 December 2021 €36,000 (31 December 2020: €25,500) in aggregate and do not receive variable remuneration. These fees are set at a level that reflects the qualifications and contribution required taking into account the Company's size, internal organisation and the nature, scope and complexity of its activities.